Alfred1007的个人主页 - 老虎社区

Alfred1007

Alfred1007

暂无个人介绍

IP属地：未知

161关注

69粉丝

0主题

0勋章

2021-12-27

Looks like payment company need few more months to revivie fully

外媒头条：奥密克戎重挫航空旅行！周日数千个航班被取消

2021-12-21

First mover advantage applies here as well

抱歉，原内容已删除

2021-12-21

Hope the treatment for other blood disorder such as thalassemia will have a breakthrough soon as well!

Bluebird Bio Shares Drop 20% After Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Program

2021-12-21

Should fall until after christmas, let's see next week!

Mega-cap growth stocks extended their fall from the previous session

2021-12-12

Stay invest!

抱歉，原内容已删除

2021-12-12

Will we need to get covid 19 booster shot like what we do for seasonal flu?

抱歉，原内容已删除

2021-12-11

Same fate with winter sea group

Grab shares dropped another 9% in morning trading

2021-12-11

Crowdstrike looks like a solid choice here

The Smartest Stocks to Buy With $200 in December

2021-12-11

Wait till next week after Fed meeting then only decide what is the next step

抱歉，原内容已删除

2021-12-11

There is no real trust between two countries now..

抱歉，原内容已删除

2021-12-11

Tapering and rising interest rate will come sooner I guess

抱歉，原内容已删除

2021-12-09

Expect to ride roller coaster again

抱歉，原内容已删除

2021-12-08

Not the Merck listes in US..

Merck invests nearly $700 million in M Ventures to seed young companies

2021-12-08

Stay invest...

Goldman Sachs Has Bad News for Investors Rushing to Buy the Dip

2021-12-07

Santa claus is coming to town..time to do some shopping!

Speedy Dip-Buying Mini S&P Corrections Has Become a Market Habit

2021-12-06

Lost the magic touch? Let's observe few more quarters.

Disney's 'Encanto' Leads Another Quiet Weekend at Box Office

2021-12-06

I guess we already get used to this...

Goldman Sachs cuts U.S. GDP growth forecast for 2022 over Omicron fears

2021-12-04

HODL!

抱歉，原内容已删除

2021-11-30

Bought some to keep!

Will This Beaten-Down Stock Bounce Back? 3 Things to Know

2021-11-25

In the future, without the internet we can literally do nothing...good or bad?

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3570656625926041,"uuid":"3570656625926041","gmtCreate":1607567977420,"gmtModify":1613043946927,"name":"Alfred1007","pinyin":"alfred1007","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":69,"headSize":161,"tweetSize":958,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.20","exceedPercentage":"80.77%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"61.00%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":698743979,"gmtCreate":1640564710880,"gmtModify":1640564933487,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Looks like payment company need few more months to revivie fully","listText":"Looks like payment company need few more months to revivie fully","text":"Looks like payment company need few more months to revivie fully","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698743979","repostId":"2194177763","repostType":2,"repost":{"id":"2194177763","pubTimestamp":1640555213,"share":"https://www.laohu8.com/m/news/2194177763?lang=&edition=full","pubTime":"2021-12-27 05:46","market":"us","language":"zh","title":"外媒头条：奥密克戎重挫航空旅行！周日数千个航班被取消","url":"https://stock-news.laohu8.com/highlight/detail?id=2194177763","media":"市场资讯","summary":"　　周日，美国数百个航班和全球数千个航班被取消，原因是在今年最繁忙的一个周末，奥密克戎变种病毒导致机组人员患病。　　据提供航空数据的FlightAware称，截至周日中午，至少有一站在美国的750多个航班被取消，而全球航班的取消数字则是其10倍。　　周日的惨淡记录是在圣诞前夜和圣诞节期间全球数千次航班取消之后出现的。取消航班可能会打乱旅行计划，而此时许多人正乘飞机与家人共度圣诞假期。","content":"<p><b>全球财经媒体昨夜今晨共同关注的头条新闻主要有：</b></p>\n<blockquote>\n <b>1、奥密克戎重挫航空旅行 周日全球数千个航班被取消</b>\n</blockquote>\n<blockquote>\n <b>2、疫情下世界各国收紧新年庆典防疫政策 多地取消活动</b>\n</blockquote>\n<blockquote>\n <b>3、福奇警告美国人不要对病毒掉以轻心 医院有可能被挤爆</b>\n</blockquote>\n<blockquote>\n <b>4、英国智库：世界经济规模预计在明年超过100万亿美元</b>\n</blockquote>\n<blockquote>\n <b>5、土耳其颁布新措施救市 里拉短时间内大幅度反弹</b>\n</blockquote>\n<blockquote>\n <b>6、<a href=\"https://laohu8.com/S/MA\">万事达</a>报告称假日销售飙升 电子商务获得巨大收益</b>\n</blockquote>\n<p><img src=\"https://static.tigerbbs.com/c3ba1ba0a72a5c08f91ca9cb2fb61ccf\" tg-width=\"550\" tg-height=\"366\" referrerpolicy=\"no-referrer\"></p>\n<p><b>奥密克戎重挫航空旅行 周日全球数千个航班被取消</b></p>\n<p>周日，美国数百个航班和全球数千个航班被取消，原因是在今年最繁忙的一个周末，奥密克戎变种病毒导致机组人员患病。</p>\n<p>据提供航空数据的FlightAware称，截至周日中午，至少有一站在美国的750多个航班被取消，而全球航班的取消数字则是其10倍。</p>\n<p>周日的惨淡记录是在圣诞前夜和圣诞节期间全球数千次航班取消之后出现的。取消航班可能会打乱旅行计划，而此时许多人正乘飞机与家人共度圣诞假期。在美国，这一传统今年似乎有所反弹：根据交通安全管理局（Transportation Security Administration）的数据，上周每天大约有200万人通过安检，而平安夜和圣诞节的人数几乎是去年的两倍。</p>\n<p><img src=\"https://static.tigerbbs.com/b4003025308bf64f066cd7aed5a06db1\" tg-width=\"550\" tg-height=\"291\" referrerpolicy=\"no-referrer\"></p>\n<p><b>疫情下世界各国收紧新年庆典防疫政策 多地取消活动</b></p>\n<p>由于新冠omicron变种的传播，世界各地的大城市正在取消他们的新年庆祝活动，而其他城市正在推进他们的计划。</p>\n<p>纽约市标志性的新年庆祝活动将如期举行，但市长比尔·德布拉<a href=\"https://laohu8.com/S/SIAL\">西奥</a>表示，由于奥密克戎变异病毒的传播，参加派对的人将不得不接受全面接种，戴上口罩，并采取社交疏远措施，活动因此将“缩减规模”。</p>\n<p>这位美国最大城市的市长解释说：“纽约人在过去的一年里取得了巨大的进步——我们在疫苗接种方面处于领先地位，我们已经安全地重新开放，每天我们都在努力为我们所有人建设一个恢复期．．．．．．有很多值得庆祝的事情，这些额外的安全措施将在新年来临之际让接种疫苗的人群保持安全和健康。”</p>\n<p>全球其他城市采取了不同的做法，有的完全取消了庆祝活动。</p>\n<p><img src=\"https://static.tigerbbs.com/c2abf615da9d23bee2f444dbfcb67f75\" tg-width=\"550\" tg-height=\"366\" referrerpolicy=\"no-referrer\"></p>\n<p><b>福奇警告美国人不要对病毒掉以轻心 医院有可能被挤爆</b></p>\n<p>美国总统拜登的首席医学顾问福奇周日表示，尽管迹象表明omicron的症状可能不那么严重，但美国人仍应保持警惕，因为病患数量可能导致医院不堪重负。</p>\n<p>福奇在节目“This Week”上对记者Jonathan Karl说，“我们不希望看到大家掉以轻心，虽然omicron的病症不严重，但出现这么多新确诊病例可能抵消该因素”。</p>\n<p>来自苏格兰的初步数据显示，omicron“带来的住院风险比德尔塔低三分之二”，研究同时也表明，omicron导致二次感染新冠病毒的可能性是德尔塔的10倍左右。</p>\n<p>据报道，美国单日新增omicron感染病例已超过德尔塔病毒感染者，<a href=\"https://laohu8.com/S/AAL\">美国航空</a>企业在长周末假期取消了近1，900个航班，因为病例激增导致工作人员短缺。</p>\n<p><img src=\"https://static.tigerbbs.com/a5dc1c2269bd67acb592df752986ba66\" tg-width=\"550\" tg-height=\"343\" referrerpolicy=\"no-referrer\"></p>\n<p><b>英国智库：世界经济规模预计在明年超过100万亿美元</b></p>\n<p>根据一份预测，2022年世界经济规模势将首次超过100万亿美元，比先前预测的时间提早两年。</p>\n<p>总部位于英国伦敦的经济与商业研究中心（Centre for Economics and Business Research， CEBR）认为，全球国内生产总值（GDP）将受到疫情持续复苏的提振，不过如果通胀持续，决策者可能很难防止经济再度陷入衰退。</p>\n<p>“21世纪20年代的重要问题是全球经济体如何应对通胀，” CEBR副主席Douglas McWilliams表示。 “我们希望能用相对温和的调整来使得非暂时性因素得到控制。如果不这样，那么世界将需要为2023年或2024年的经济衰退做好准备。”</p>\n<p><img src=\"https://static.tigerbbs.com/4fd25fb23bbaab45631729cf6e09db84\" tg-width=\"500\" tg-height=\"333\" referrerpolicy=\"no-referrer\"></p>\n<p><b>土耳其颁布新措施救市 里拉短时间内大幅度反弹</b></p>\n<p>土耳其里拉本周走出一波大幅上涨行情，里拉对美元汇率由20日的18比1左右急速攀升至最高时的10比1左右，最终维持在11比1左右，涨幅逾40%，回到上月中下旬时的水平。</p>\n<p>近期，里拉汇率屡现剧烈波动行情。16日，里拉对美元汇率跌破15比1大关；17日，里拉对美元汇率跌破16和17两个整数关口；20日，里拉对美元汇率跌破18比1大关。本月以来，土耳其<a href=\"https://laohu8.com/S/CNBC\">中央银行</a>已经五次干预外汇市场。</p>\n<p>20日晚，土耳其总统埃尔多安宣布新救市措施，里拉汇率随即一转颓势，大幅上扬并逐渐企稳。救市措施包括一项新的金融替代方案，为本币储蓄因里拉贬值蒙受的损失提供补偿，以减少汇率波动对储户的影响。同时，政府将采取大幅提高个人养老金补贴等措施，以减轻民众生活成本压力。</p>\n<p><img src=\"https://static.tigerbbs.com/9e1d7eff89b4a5234ad828b7dca303d5\" tg-width=\"550\" tg-height=\"309\" referrerpolicy=\"no-referrer\"></p>\n<p><b>万事达报告称假日销售飙升 电子商务获得巨大收益</b></p>\n<p>根据万事达卡（Mastercard）周日发布的一份报告，与2019年的假日期间相比，美国本季度的零售额增长了近11%。2019年是新冠大流行颠覆全球经济的前一年。</p>\n<p>这份名为Mastercard SpendingPulse的报告显示，与去年相比，在11月1日至12月24日的假日期间，零售销售额增长了8.5%。这些数据不包括汽车销售。</p>\n<p>与去年相比，实体店的销售额增长了8.1%，电子商务销售额增长了11%。与2019年相比，在新冠肺炎疫情导致网上订单激增之前，电子商务销售额增长了61%以上。</p>\n<p>根据万事达卡的报告，今年网上销售占零售总额的20.9%。2019年，在线销售仅占所有零售销售的14.6%，突显出疫情如何加速了向电子商务的转变。</p>\n<p>万事达卡高级顾问史蒂夫·萨多夫在一份声明中表示，许多美国人今年提前完成了圣诞购物。他说：“购物者急于在零售热潮到来之前确保自己的礼物，对供应链和劳动力供应问题的讨论让消费者成群结队地来到网上和商店（进行消费）。”</p>","source":"sina_us","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>外媒头条：奥密克戎重挫航空旅行！周日数千个航班被取消</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n外媒头条：奥密克戎重挫航空旅行！周日数千个航班被取消\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 05:46 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2021-12-27/doc-ikyakumx6577426.shtml><strong>市场资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>全球财经媒体昨夜今晨共同关注的头条新闻主要有：\n\n1、奥密克戎重挫航空旅行 周日全球数千个航班被取消\n\n\n2、疫情下世界各国收紧新年庆典防疫政策 多地取消活动\n\n\n3、福奇警告美国人不要对病毒掉以轻心 医院有可能被挤爆\n\n\n4、英国智库：世界经济规模预计在明年超过100万亿美元\n\n\n5、土耳其颁布新措施救市 里拉短时间内大幅度反弹\n\n\n6、万事达报告称假日销售飙升 电子商务获得巨大收益\n\n\n...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2021-12-27/doc-ikyakumx6577426.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c2abf615da9d23bee2f444dbfcb67f75","relate_stocks":{"MA":"万事达",".DJI":"道琼斯","BK4559":"巴菲特持仓","BK4527":"明星科技股","GDP":"古德里奇","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4213":"石油与天然气的勘探与生产",".IXIC":"NASDAQ Composite","BK4106":"数据处理与外包服务",".SPX":"S&P 500 Index","BK4566":"资本集团","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓"},"source_url":"https://finance.sina.com.cn/stock/usstock/c/2021-12-27/doc-ikyakumx6577426.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2194177763","content_text":"全球财经媒体昨夜今晨共同关注的头条新闻主要有：\n\n1、奥密克戎重挫航空旅行 周日全球数千个航班被取消\n\n\n2、疫情下世界各国收紧新年庆典防疫政策 多地取消活动\n\n\n3、福奇警告美国人不要对病毒掉以轻心 医院有可能被挤爆\n\n\n4、英国智库：世界经济规模预计在明年超过100万亿美元\n\n\n5、土耳其颁布新措施救市 里拉短时间内大幅度反弹\n\n\n6、万事达报告称假日销售飙升 电子商务获得巨大收益\n\n\n奥密克戎重挫航空旅行 周日全球数千个航班被取消\n周日，美国数百个航班和全球数千个航班被取消，原因是在今年最繁忙的一个周末，奥密克戎变种病毒导致机组人员患病。\n据提供航空数据的FlightAware称，截至周日中午，至少有一站在美国的750多个航班被取消，而全球航班的取消数字则是其10倍。\n周日的惨淡记录是在圣诞前夜和圣诞节期间全球数千次航班取消之后出现的。取消航班可能会打乱旅行计划，而此时许多人正乘飞机与家人共度圣诞假期。在美国，这一传统今年似乎有所反弹：根据交通安全管理局（Transportation Security Administration）的数据，上周每天大约有200万人通过安检，而平安夜和圣诞节的人数几乎是去年的两倍。\n\n疫情下世界各国收紧新年庆典防疫政策 多地取消活动\n由于新冠omicron变种的传播，世界各地的大城市正在取消他们的新年庆祝活动，而其他城市正在推进他们的计划。\n纽约市标志性的新年庆祝活动将如期举行，但市长比尔·德布拉西奥表示，由于奥密克戎变异病毒的传播，参加派对的人将不得不接受全面接种，戴上口罩，并采取社交疏远措施，活动因此将“缩减规模”。\n这位美国最大城市的市长解释说：“纽约人在过去的一年里取得了巨大的进步——我们在疫苗接种方面处于领先地位，我们已经安全地重新开放，每天我们都在努力为我们所有人建设一个恢复期．．．．．．有很多值得庆祝的事情，这些额外的安全措施将在新年来临之际让接种疫苗的人群保持安全和健康。”\n全球其他城市采取了不同的做法，有的完全取消了庆祝活动。\n\n福奇警告美国人不要对病毒掉以轻心 医院有可能被挤爆\n美国总统拜登的首席医学顾问福奇周日表示，尽管迹象表明omicron的症状可能不那么严重，但美国人仍应保持警惕，因为病患数量可能导致医院不堪重负。\n福奇在节目“This Week”上对记者Jonathan Karl说，“我们不希望看到大家掉以轻心，虽然omicron的病症不严重，但出现这么多新确诊病例可能抵消该因素”。\n来自苏格兰的初步数据显示，omicron“带来的住院风险比德尔塔低三分之二”，研究同时也表明，omicron导致二次感染新冠病毒的可能性是德尔塔的10倍左右。\n据报道，美国单日新增omicron感染病例已超过德尔塔病毒感染者，美国航空企业在长周末假期取消了近1，900个航班，因为病例激增导致工作人员短缺。\n\n英国智库：世界经济规模预计在明年超过100万亿美元\n根据一份预测，2022年世界经济规模势将首次超过100万亿美元，比先前预测的时间提早两年。\n总部位于英国伦敦的经济与商业研究中心（Centre for Economics and Business Research， CEBR）认为，全球国内生产总值（GDP）将受到疫情持续复苏的提振，不过如果通胀持续，决策者可能很难防止经济再度陷入衰退。\n“21世纪20年代的重要问题是全球经济体如何应对通胀，” CEBR副主席Douglas McWilliams表示。 “我们希望能用相对温和的调整来使得非暂时性因素得到控制。如果不这样，那么世界将需要为2023年或2024年的经济衰退做好准备。”\n\n土耳其颁布新措施救市 里拉短时间内大幅度反弹\n土耳其里拉本周走出一波大幅上涨行情，里拉对美元汇率由20日的18比1左右急速攀升至最高时的10比1左右，最终维持在11比1左右，涨幅逾40%，回到上月中下旬时的水平。\n近期，里拉汇率屡现剧烈波动行情。16日，里拉对美元汇率跌破15比1大关；17日，里拉对美元汇率跌破16和17两个整数关口；20日，里拉对美元汇率跌破18比1大关。本月以来，土耳其中央银行已经五次干预外汇市场。\n20日晚，土耳其总统埃尔多安宣布新救市措施，里拉汇率随即一转颓势，大幅上扬并逐渐企稳。救市措施包括一项新的金融替代方案，为本币储蓄因里拉贬值蒙受的损失提供补偿，以减少汇率波动对储户的影响。同时，政府将采取大幅提高个人养老金补贴等措施，以减轻民众生活成本压力。\n\n万事达报告称假日销售飙升 电子商务获得巨大收益\n根据万事达卡（Mastercard）周日发布的一份报告，与2019年的假日期间相比，美国本季度的零售额增长了近11%。2019年是新冠大流行颠覆全球经济的前一年。\n这份名为Mastercard SpendingPulse的报告显示，与去年相比，在11月1日至12月24日的假日期间，零售销售额增长了8.5%。这些数据不包括汽车销售。\n与去年相比，实体店的销售额增长了8.1%，电子商务销售额增长了11%。与2019年相比，在新冠肺炎疫情导致网上订单激增之前，电子商务销售额增长了61%以上。\n根据万事达卡的报告，今年网上销售占零售总额的20.9%。2019年，在线销售仅占所有零售销售的14.6%，突显出疫情如何加速了向电子商务的转变。\n万事达卡高级顾问史蒂夫·萨多夫在一份声明中表示，许多美国人今年提前完成了圣诞购物。他说：“购物者急于在零售热潮到来之前确保自己的礼物，对供应链和劳动力供应问题的讨论让消费者成群结队地来到网上和商店（进行消费）。”","news_type":1},"isVote":1,"tweetType":1,"viewCount":526,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693539490,"gmtCreate":1640048021439,"gmtModify":1640048022160,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"First mover advantage applies here as well","listText":"First mover advantage applies here as well","text":"First mover advantage applies here as well","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693539490","repostId":"1167477980","repostType":4,"isVote":1,"tweetType":1,"viewCount":562,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693597202,"gmtCreate":1640047790727,"gmtModify":1640053178478,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Hope the treatment for other blood disorder&nbsp; such as&nbsp;thalassemia will have a breakthrough soon as well!","listText":"Hope the treatment for other blood disorder&nbsp; such as&nbsp;thalassemia will have a breakthrough soon as well!","text":"Hope the treatment for other blood disorder such as thalassemia will have a breakthrough soon as well!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693597202","repostId":"1110189962","repostType":4,"repost":{"id":"1110189962","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1640009269,"share":"https://www.laohu8.com/m/news/1110189962?lang=&edition=full","pubTime":"2021-12-20 22:07","market":"us","language":"en","title":" Bluebird Bio Shares Drop 20% After Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Program","url":"https://stock-news.laohu8.com/highlight/detail?id=1110189962","media":"Dow Jones","summary":"Bluebird bio Inc.'s shares were sharply lower early Monday after the Food and Drug Administration pl","content":"<p>Bluebird bio Inc.'s shares were sharply lower early Monday after the Food and Drug Administration placed a partial hold on the company's clinical program for lovotibeglogene autotemcel gene therapy for sickle cell disease.</p>\n<p>The partial, temporary suspension for patients under the age of 18 relates to an investigation by bluebird bio into an adolescent patient with persistent, non-transfusion-dependent anemia following treatment with lovo-cel, now 18 months post-treatment, the company said.</p>\n<p>In premarket trading, the shares were 20% lower after closing last week at $10.62, down more than 60% since the end of last year.</p>\n<p>Bluebird said the adolescent patient is clinically well and there is no evidence of malignancy or clonal predominance.</p>\n<p>Enrollment and dosing for patients 18 and older living with sickle cell disease in its HGB-206, HGB-210 and LTF-307 clinical studies, as well as follow up for treated patients of all ages in all studies, are continuing as planned, the company said.</p>\n<p>\"We have paused enrollment and treatment of patients younger than 18 in our SCD clinical program, and we will continue to work collaboratively with the FDA to understand and address their concerns,\" Chief Medical Officer Richard Colvin said.</p>\n<p>The company said it expects written questions from the FDA in early 2022 and will work quickly to respond in order to resolve the partial hold. It said it is evaluating what impact, if any, the partial clinical hold may have on its first quarter 2023 projected timing for the lovo-cel biologics license application submission.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title> Bluebird Bio Shares Drop 20% After Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n Bluebird Bio Shares Drop 20% After Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-20 22:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Bluebird bio Inc.'s shares were sharply lower early Monday after the Food and Drug Administration placed a partial hold on the company's clinical program for lovotibeglogene autotemcel gene therapy for sickle cell disease.</p>\n<p>The partial, temporary suspension for patients under the age of 18 relates to an investigation by bluebird bio into an adolescent patient with persistent, non-transfusion-dependent anemia following treatment with lovo-cel, now 18 months post-treatment, the company said.</p>\n<p>In premarket trading, the shares were 20% lower after closing last week at $10.62, down more than 60% since the end of last year.</p>\n<p>Bluebird said the adolescent patient is clinically well and there is no evidence of malignancy or clonal predominance.</p>\n<p>Enrollment and dosing for patients 18 and older living with sickle cell disease in its HGB-206, HGB-210 and LTF-307 clinical studies, as well as follow up for treated patients of all ages in all studies, are continuing as planned, the company said.</p>\n<p>\"We have paused enrollment and treatment of patients younger than 18 in our SCD clinical program, and we will continue to work collaboratively with the FDA to understand and address their concerns,\" Chief Medical Officer Richard Colvin said.</p>\n<p>The company said it expects written questions from the FDA in early 2022 and will work quickly to respond in order to resolve the partial hold. It said it is evaluating what impact, if any, the partial clinical hold may have on its first quarter 2023 projected timing for the lovo-cel biologics license application submission.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLUE":"bluebird bio Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110189962","content_text":"Bluebird bio Inc.'s shares were sharply lower early Monday after the Food and Drug Administration placed a partial hold on the company's clinical program for lovotibeglogene autotemcel gene therapy for sickle cell disease.\nThe partial, temporary suspension for patients under the age of 18 relates to an investigation by bluebird bio into an adolescent patient with persistent, non-transfusion-dependent anemia following treatment with lovo-cel, now 18 months post-treatment, the company said.\nIn premarket trading, the shares were 20% lower after closing last week at $10.62, down more than 60% since the end of last year.\nBluebird said the adolescent patient is clinically well and there is no evidence of malignancy or clonal predominance.\nEnrollment and dosing for patients 18 and older living with sickle cell disease in its HGB-206, HGB-210 and LTF-307 clinical studies, as well as follow up for treated patients of all ages in all studies, are continuing as planned, the company said.\n\"We have paused enrollment and treatment of patients younger than 18 in our SCD clinical program, and we will continue to work collaboratively with the FDA to understand and address their concerns,\" Chief Medical Officer Richard Colvin said.\nThe company said it expects written questions from the FDA in early 2022 and will work quickly to respond in order to resolve the partial hold. It said it is evaluating what impact, if any, the partial clinical hold may have on its first quarter 2023 projected timing for the lovo-cel biologics license application submission.","news_type":1},"isVote":1,"tweetType":1,"viewCount":582,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693594028,"gmtCreate":1640047667325,"gmtModify":1640047668047,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Should fall until after christmas, let's see next week!","listText":"Should fall until after christmas, let's see next week!","text":"Should fall until after christmas, let's see next week!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693594028","repostId":"1115322314","repostType":4,"repost":{"id":"1115322314","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640011665,"share":"https://www.laohu8.com/m/news/1115322314?lang=&edition=full","pubTime":"2021-12-20 22:47","market":"us","language":"en","title":"Mega-cap growth stocks extended their fall from the previous session","url":"https://stock-news.laohu8.com/highlight/detail?id=1115322314","media":"Tiger Newspress","summary":"Mega-cap growth stocks extended their fall from the previous session, with Apple, Meta Platforms and","content":"<p>Mega-cap growth stocks extended their fall from the previous session, with&nbsp;Apple, Meta Platforms&nbsp;and Microsoft Corp&nbsp;down between 1% and 3%.</p>\n<p><img src=\"https://static.tigerbbs.com/bcbe2eb85bd02485d4f915039e5a7c33\" tg-width=\"709\" tg-height=\"607\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mega-cap growth stocks extended their fall from the previous session</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMega-cap growth stocks extended their fall from the previous session\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-20 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mega-cap growth stocks extended their fall from the previous session, with&nbsp;Apple, Meta Platforms&nbsp;and Microsoft Corp&nbsp;down between 1% and 3%.</p>\n<p><img src=\"https://static.tigerbbs.com/bcbe2eb85bd02485d4f915039e5a7c33\" tg-width=\"709\" tg-height=\"607\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果","AMZN":"亚马逊","MSFT":"微软"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115322314","content_text":"Mega-cap growth stocks extended their fall from the previous session, with Apple, Meta Platforms and Microsoft Corp down between 1% and 3%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":590,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604998302,"gmtCreate":1639298384896,"gmtModify":1639298385556,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Stay invest!&nbsp;","listText":"Stay invest!&nbsp;","text":"Stay invest!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604998302","repostId":"2190671759","repostType":2,"isVote":1,"tweetType":1,"viewCount":647,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604991842,"gmtCreate":1639298215010,"gmtModify":1639298960595,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Will we need to get covid 19 booster shot like what we do for seasonal flu?","listText":"Will we need to get covid 19 booster shot like what we do for seasonal flu?","text":"Will we need to get covid 19 booster shot like what we do for seasonal flu?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604991842","repostId":"2190674843","repostType":2,"isVote":1,"tweetType":1,"viewCount":886,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605516242,"gmtCreate":1639189833090,"gmtModify":1639190173073,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Same fate with winter sea group","listText":"Same fate with winter sea group","text":"Same fate with winter sea group","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605516242","repostId":"1134450838","repostType":4,"repost":{"id":"1134450838","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639148939,"share":"https://www.laohu8.com/m/news/1134450838?lang=&edition=full","pubTime":"2021-12-10 23:08","market":"us","language":"en","title":"Grab shares dropped another 9% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1134450838","media":"Tiger Newspress","summary":"Grab shares dropped another 9% in morning trading after falling more than 9% yesterday.","content":"<p>Grab shares dropped another 9% in morning trading after falling more than 9% yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/963eb8dd73ce8daa0d852d63f0bcc276\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab shares dropped another 9% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab shares dropped another 9% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-10 23:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Grab shares dropped another 9% in morning trading after falling more than 9% yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/963eb8dd73ce8daa0d852d63f0bcc276\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134450838","content_text":"Grab shares dropped another 9% in morning trading after falling more than 9% yesterday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":727,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605511062,"gmtCreate":1639189567159,"gmtModify":1639190162127,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Crowdstrike looks like a solid choice here","listText":"Crowdstrike looks like a solid choice here","text":"Crowdstrike looks like a solid choice here","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605511062","repostId":"2190296066","repostType":4,"repost":{"id":"2190296066","pubTimestamp":1639150220,"share":"https://www.laohu8.com/m/news/2190296066?lang=&edition=full","pubTime":"2021-12-10 23:30","market":"us","language":"en","title":"The Smartest Stocks to Buy With $200 in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2190296066","media":"Motley Fool","summary":"A small investment can go a long way with this mix of growth, income, and value stocks.","content":"<p>Despite volatility rearing its head over the past couple of weeks, it's been another stellar year for the stock market. Through Dec. 6, the benchmark <b>S&amp;P 500</b> has gained 22% on a year-to-date basis. That essentially doubles up the average annual total return, including dividends, of the S&amp;P 500 since 1980 (about 11%).</p>\n<p>But just because the broader market is up big, it doesn't mean there aren't still bargains to be found. For patient investors who lean on time as their ally, there are plenty of stocks that can make them richer.</p>\n<p>Best of all, you don't need a mountain of money to build wealth on Wall Street. With most brokerages eliminating minimum deposit requirements and trading commissions, any amount of money -- even $200 -- can be the right amount to grow your portfolio.</p>\n<p>If you have $200 ready to invest, the following are some of the smartest stocks you can buy in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5876cf8596571681f0d3218da4f74c8c\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>CrowdStrike Holdings</h2>\n<p>One of the smartest buys investors can make is scooping up shares of premier cybersecurity stock <b>CrowdStrike Holdings</b> (NASDAQ:CRWD).</p>\n<p>Cybersecurity may not be the fastest-growing trend, but there's arguably not a safer double-digit growth opportunity through the midpoint of the decade. Since hackers and robots don't take time off just because the U.S. economy or stock market hit a rough patch, businesses are increasingly turning to third-party providers to secure their data and that of their clients.</p>\n<p>What makes CrowdStrike special is its cloud-native Falcon security platform. Falcon relies on artificial intelligence to grow smarter over time and is currently overseeing about 1 trillion events <i>per day</i>. As a cloud-based platform, Falcon is often better at recognizing and responding to threats than on-premises solutions. While CrowdStrike's solutions aren't the cheapest on a nominal basis, the long-term reward of data protection makes Falcon a more cost-effective platform for businesses.</p>\n<p>The proof is in the pudding that clients are thrilled with CrowdStrike's suite of services. The total number of subscribers has skyrocketed from 450 to almost 14,700 in less than five years, with 68% of its clients purchasing four or more cloud-module subscriptions, as of Sept. 30. The latter is up from under 10% less than five years ago. The company's customer retention rate has also hovered around 98% for two years running.</p>\n<p>CrowdStrike's stock isn't inexpensive using standard fundamental metrics. However, a valuation premium is certainly warranted with its subscription gross margin already at its long-term target this early in its expansion.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/626f702dc64e03a6186f9231d5b698b4\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AT&amp;T</h2>\n<p>Keep in mind that it's not just growth stocks that are begging to be bought. Value and income plays like telecom stock <b>AT&amp;T</b> (NYSE:T) represent a smart way to put $200 to work right now.</p>\n<p>To state the obvious, AT&amp;T's high-growth heyday is long gone. But just because the company has matured, it doesn't mean there aren't organic growth opportunities on its doorstep.</p>\n<p>For instance, AT&amp;T should benefit nicely from the ongoing rollout of 5G wireless infrastructure. Although upgrading its infrastructure won't be cheap, the investment will pay off handsomely. That's because it's been a decade since wireless download speeds were meaningfully improved. With 5G becoming widely available, consumers and businesses are liable to undertake a multiyear device upgrade cycle to take advantage of a faster network. Since the bulk of AT&amp;T's wireless margins derive from data consumption, 5G should provide a healthy shot of organic growth through at least 2025.</p>\n<p>AT&amp;T is also in the process of spinning off its content arm, WarnerMedia, and combining it with <b>Discovery</b>&nbsp;to create a new media powerhouse. The new company should have over 85 million streaming subscribers, a more diverse content library, and it'll be able to cut its operating costs by over $3 billion a year.</p>\n<p>At an estimated 7 times forecasted earnings per share this year, and a high-yield dividend to boot, AT&amp;T is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the smartest value and income plays to buy now.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5aacd35062c7935f82d018ba2d593ab6\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Exelixis</h2>\n<p>Another genius purchase investors can make in December with $200 is biotech stock <b>Exelixis</b> (NASDAQ:EXEL).</p>\n<p>Exelixis has had a bit of a rough year, with its shares down close to 20%. The cancer-focused drug developer disappointed Wall Street in late June when it unveiled interim analysis data from the late-stage Cosmic-312 study in patients with previously untreated liver cancer. The company's lead drug, Cabometyx, was paired with atezolizumab (better known by its brand name, Tecentriq) in this study. While progression-free survival data hit the mark, the company noted it was unlikely that overall survival data would show a statistically significant improvement versus Nexavar.</p>\n<p>Though this was undoubtedly disappointing, as first-line hepatocellular carcinoma (HCC) is an indication that could use more-effective treatments, the downside Exelixis' shares have seen since this data release looks to be an overreaction.</p>\n<p>Even assuming the Food and Drug Administration doesn't grant this combo treatment approval in first-line HCC -- the company plans to file a supplemental new drug application in Q1 2022 -- Cabometyx is in line for well over $1 billion in annual revenue from first- and second-line kidney cancer indications and more advanced cases of HCC.</p>\n<p>Furthermore, Cabometyx is being examined in close to six dozen clinical trials. Some failures are expected. But if even a handful of these studies result in label expansion opportunities, Cabometyx could surpass $2 billion in annual sales.</p>\n<p>With Exelixis sitting on a whopping $1.8 billion in cash, cash equivalents, and restricted cash equivalents and investments (this is about 35% of its market cap), and the company's price-earnings-to-growth ratio well below 1, it has all the hallmarks of a screaming buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b13f98298635a74f4491a99bf47eeded\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/WBA\">Walgreens Boots Alliance</a></h2>\n<p>A final smart stock investors can buy with $200 in December is pharmacy chain <b>Walgreens Boots Alliance</b> (NASDAQ:WBA). Similar to AT&amp;T, this is another value/income play that's not getting the love it deserves.</p>\n<p>Normally, healthcare stocks aren't adversely affected by economic downturns. Since we can't control when we get sick or what ailment(s) we develop, there's always demand for drugs, devices, and healthcare services. But during the pandemic, Walgreens wasn't as lucky. Reduced foot traffic hurt demand for front-end sales and clinic revenue.</p>\n<p>That's the bad news. The good news is Walgreens is incredibly inexpensive following the worst of the pandemic, and it's already well into a multipoint turnaround plan designed to increase margins and boost its organic growth rate.</p>\n<p>Initially, management anticipated reducing annual operating expenses by $2 billion as of the end of fiscal 2022. But cost-cutting activity has been far better than expected. Walgreens achieved more than $2 billion in annual cost reductions, and it did so by the end of fiscal 2021.</p>\n<p>However, it's not cost-cutting that should have investors excited. Rather, it's the company's investments. For example, Walgreens has spared no expense when it comes to its investments in digitization. Placing greater emphasis on direct-to-consumer sales should result in sustainable double-digit online revenue growth.</p>\n<p>Walgreens has also partnered with VillageMD to open more than 600 full-service clinics in over 30 U.S. markets by 2025. These co-located clinics will be physician-staffed and should play a key role in funneling local residents to the company's higher-margin pharmacy.</p>\n<p>At less than 10 times Wall Street's forecasted earnings per share for fiscal 2022, Walgreens Boots Alliance is a steal.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Smartest Stocks to Buy With $200 in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Smartest Stocks to Buy With $200 in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/10/the-smartest-stocks-to-buy-with-200-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite volatility rearing its head over the past couple of weeks, it's been another stellar year for the stock market. Through Dec. 6, the benchmark S&P 500 has gained 22% on a year-to-date basis. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/10/the-smartest-stocks-to-buy-with-200-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRWD":"CrowdStrike Holdings, Inc.","BK4534":"瑞士信贷持仓","BK4097":"系统软件","BK4507":"流媒体概念","BK4006":"钢铁","T":"美国电话电报","BK4139":"生物科技","HCC":"Warrior Met Coal LLC","BK4528":"SaaS概念","BK4550":"红杉资本持仓","BK4560":"网络安全概念","BK4128":"药品零售","WBA":"沃尔格林联合博姿","BK4115":"综合电信业务","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","EXEL":"伊克力西斯","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2021/12/10/the-smartest-stocks-to-buy-with-200-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190296066","content_text":"Despite volatility rearing its head over the past couple of weeks, it's been another stellar year for the stock market. Through Dec. 6, the benchmark S&P 500 has gained 22% on a year-to-date basis. That essentially doubles up the average annual total return, including dividends, of the S&P 500 since 1980 (about 11%).\nBut just because the broader market is up big, it doesn't mean there aren't still bargains to be found. For patient investors who lean on time as their ally, there are plenty of stocks that can make them richer.\nBest of all, you don't need a mountain of money to build wealth on Wall Street. With most brokerages eliminating minimum deposit requirements and trading commissions, any amount of money -- even $200 -- can be the right amount to grow your portfolio.\nIf you have $200 ready to invest, the following are some of the smartest stocks you can buy in December.\nImage source: Getty Images.\nCrowdStrike Holdings\nOne of the smartest buys investors can make is scooping up shares of premier cybersecurity stock CrowdStrike Holdings (NASDAQ:CRWD).\nCybersecurity may not be the fastest-growing trend, but there's arguably not a safer double-digit growth opportunity through the midpoint of the decade. Since hackers and robots don't take time off just because the U.S. economy or stock market hit a rough patch, businesses are increasingly turning to third-party providers to secure their data and that of their clients.\nWhat makes CrowdStrike special is its cloud-native Falcon security platform. Falcon relies on artificial intelligence to grow smarter over time and is currently overseeing about 1 trillion events per day. As a cloud-based platform, Falcon is often better at recognizing and responding to threats than on-premises solutions. While CrowdStrike's solutions aren't the cheapest on a nominal basis, the long-term reward of data protection makes Falcon a more cost-effective platform for businesses.\nThe proof is in the pudding that clients are thrilled with CrowdStrike's suite of services. The total number of subscribers has skyrocketed from 450 to almost 14,700 in less than five years, with 68% of its clients purchasing four or more cloud-module subscriptions, as of Sept. 30. The latter is up from under 10% less than five years ago. The company's customer retention rate has also hovered around 98% for two years running.\nCrowdStrike's stock isn't inexpensive using standard fundamental metrics. However, a valuation premium is certainly warranted with its subscription gross margin already at its long-term target this early in its expansion.\nImage source: Getty Images.\nAT&T\nKeep in mind that it's not just growth stocks that are begging to be bought. Value and income plays like telecom stock AT&T (NYSE:T) represent a smart way to put $200 to work right now.\nTo state the obvious, AT&T's high-growth heyday is long gone. But just because the company has matured, it doesn't mean there aren't organic growth opportunities on its doorstep.\nFor instance, AT&T should benefit nicely from the ongoing rollout of 5G wireless infrastructure. Although upgrading its infrastructure won't be cheap, the investment will pay off handsomely. That's because it's been a decade since wireless download speeds were meaningfully improved. With 5G becoming widely available, consumers and businesses are liable to undertake a multiyear device upgrade cycle to take advantage of a faster network. Since the bulk of AT&T's wireless margins derive from data consumption, 5G should provide a healthy shot of organic growth through at least 2025.\nAT&T is also in the process of spinning off its content arm, WarnerMedia, and combining it with Discovery to create a new media powerhouse. The new company should have over 85 million streaming subscribers, a more diverse content library, and it'll be able to cut its operating costs by over $3 billion a year.\nAt an estimated 7 times forecasted earnings per share this year, and a high-yield dividend to boot, AT&T is one of the smartest value and income plays to buy now.\nImage source: Getty Images.\nExelixis\nAnother genius purchase investors can make in December with $200 is biotech stock Exelixis (NASDAQ:EXEL).\nExelixis has had a bit of a rough year, with its shares down close to 20%. The cancer-focused drug developer disappointed Wall Street in late June when it unveiled interim analysis data from the late-stage Cosmic-312 study in patients with previously untreated liver cancer. The company's lead drug, Cabometyx, was paired with atezolizumab (better known by its brand name, Tecentriq) in this study. While progression-free survival data hit the mark, the company noted it was unlikely that overall survival data would show a statistically significant improvement versus Nexavar.\nThough this was undoubtedly disappointing, as first-line hepatocellular carcinoma (HCC) is an indication that could use more-effective treatments, the downside Exelixis' shares have seen since this data release looks to be an overreaction.\nEven assuming the Food and Drug Administration doesn't grant this combo treatment approval in first-line HCC -- the company plans to file a supplemental new drug application in Q1 2022 -- Cabometyx is in line for well over $1 billion in annual revenue from first- and second-line kidney cancer indications and more advanced cases of HCC.\nFurthermore, Cabometyx is being examined in close to six dozen clinical trials. Some failures are expected. But if even a handful of these studies result in label expansion opportunities, Cabometyx could surpass $2 billion in annual sales.\nWith Exelixis sitting on a whopping $1.8 billion in cash, cash equivalents, and restricted cash equivalents and investments (this is about 35% of its market cap), and the company's price-earnings-to-growth ratio well below 1, it has all the hallmarks of a screaming buy.\nImage source: Getty Images.\nWalgreens Boots Alliance\nA final smart stock investors can buy with $200 in December is pharmacy chain Walgreens Boots Alliance (NASDAQ:WBA). Similar to AT&T, this is another value/income play that's not getting the love it deserves.\nNormally, healthcare stocks aren't adversely affected by economic downturns. Since we can't control when we get sick or what ailment(s) we develop, there's always demand for drugs, devices, and healthcare services. But during the pandemic, Walgreens wasn't as lucky. Reduced foot traffic hurt demand for front-end sales and clinic revenue.\nThat's the bad news. The good news is Walgreens is incredibly inexpensive following the worst of the pandemic, and it's already well into a multipoint turnaround plan designed to increase margins and boost its organic growth rate.\nInitially, management anticipated reducing annual operating expenses by $2 billion as of the end of fiscal 2022. But cost-cutting activity has been far better than expected. Walgreens achieved more than $2 billion in annual cost reductions, and it did so by the end of fiscal 2021.\nHowever, it's not cost-cutting that should have investors excited. Rather, it's the company's investments. For example, Walgreens has spared no expense when it comes to its investments in digitization. Placing greater emphasis on direct-to-consumer sales should result in sustainable double-digit online revenue growth.\nWalgreens has also partnered with VillageMD to open more than 600 full-service clinics in over 30 U.S. markets by 2025. These co-located clinics will be physician-staffed and should play a key role in funneling local residents to the company's higher-margin pharmacy.\nAt less than 10 times Wall Street's forecasted earnings per share for fiscal 2022, Walgreens Boots Alliance is a steal.","news_type":1},"isVote":1,"tweetType":1,"viewCount":663,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605519516,"gmtCreate":1639189464463,"gmtModify":1639189872017,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Wait till next week after Fed meeting then only decide what is the next step","listText":"Wait till next week after Fed meeting then only decide what is the next step","text":"Wait till next week after Fed meeting then only decide what is the next step","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605519516","repostId":"1133027099","repostType":4,"isVote":1,"tweetType":1,"viewCount":627,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605537663,"gmtCreate":1639189213268,"gmtModify":1639189213970,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"There is no real trust between two countries now..","listText":"There is no real trust between two countries now..","text":"There is no real trust between two countries now..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605537663","repostId":"2190275356","repostType":4,"isVote":1,"tweetType":1,"viewCount":972,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605534085,"gmtCreate":1639188985261,"gmtModify":1639188985987,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Tapering and rising interest rate will come sooner I guess","listText":"Tapering and rising interest rate will come sooner I guess","text":"Tapering and rising interest rate will come sooner I guess","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/605534085","repostId":"2190767366","repostType":4,"isVote":1,"tweetType":1,"viewCount":306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602879580,"gmtCreate":1639010340083,"gmtModify":1639010340700,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Expect to ride roller coaster again","listText":"Expect to ride roller coaster again","text":"Expect to ride roller coaster again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602879580","repostId":"2190269318","repostType":2,"isVote":1,"tweetType":1,"viewCount":267,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602352137,"gmtCreate":1638975537286,"gmtModify":1638975537886,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Not the Merck listes in US..","listText":"Not the Merck listes in US..","text":"Not the Merck listes in US..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602352137","repostId":"2189662864","repostType":2,"repost":{"id":"2189662864","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1638970380,"share":"https://www.laohu8.com/m/news/2189662864?lang=&edition=full","pubTime":"2021-12-08 21:33","market":"us","language":"en","title":"Merck invests nearly $700 million in M Ventures to seed young companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2189662864","media":"Dow Jones","summary":"MW Merck invests nearly $700 million in M Ventures to seed young companies\n\n\n  Merck & Co. Inc.'s $(","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Merck invests nearly $700 million in M Ventures to seed young companies\n</p>\n<p>\n  Merck &amp; Co. Inc.'s <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> German unit Merck KGaA said Wednesday it will invest an additional 600 million euros ($679 million) into its corporate venture capital arm M Ventures over the next five years, Dow Jones reported. Since its inception in 2009, M Ventures has developed more than 80 companies around the world from founding to spin-off, and has backed the launch of new drugs and technologies. Shares of Merck are down 7.3% so far this year, compared to a rise of nearly 25% by the S&amp;P 500. \n</p>\n<p>\n  -Steve Gelsi \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  December 08, 2021 08:33 ET (13:33 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck invests nearly $700 million in M Ventures to seed young companies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck invests nearly $700 million in M Ventures to seed young companies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-08 21:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Merck invests nearly $700 million in M Ventures to seed young companies\n</p>\n<p>\n  Merck &amp; Co. Inc.'s <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> German unit Merck KGaA said Wednesday it will invest an additional 600 million euros ($679 million) into its corporate venture capital arm M Ventures over the next five years, Dow Jones reported. Since its inception in 2009, M Ventures has developed more than 80 companies around the world from founding to spin-off, and has backed the launch of new drugs and technologies. Shares of Merck are down 7.3% so far this year, compared to a rise of nearly 25% by the S&amp;P 500. \n</p>\n<p>\n  -Steve Gelsi \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  December 08, 2021 08:33 ET (13:33 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4516":"特朗普概念","BK4007":"制药","MRK":"默沙东"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189662864","content_text":"MW Merck invests nearly $700 million in M Ventures to seed young companies\n\n\n  Merck & Co. Inc.'s $(MRK)$ German unit Merck KGaA said Wednesday it will invest an additional 600 million euros ($679 million) into its corporate venture capital arm M Ventures over the next five years, Dow Jones reported. Since its inception in 2009, M Ventures has developed more than 80 companies around the world from founding to spin-off, and has backed the launch of new drugs and technologies. Shares of Merck are down 7.3% so far this year, compared to a rise of nearly 25% by the S&P 500. \n\n\n  -Steve Gelsi \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  December 08, 2021 08:33 ET (13:33 GMT)\n\n\n  Copyright (c) 2021 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":268,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602358922,"gmtCreate":1638975288076,"gmtModify":1638975288674,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Stay invest...","listText":"Stay invest...","text":"Stay invest...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602358922","repostId":"2189163737","repostType":4,"repost":{"id":"2189163737","pubTimestamp":1638941823,"share":"https://www.laohu8.com/m/news/2189163737?lang=&edition=full","pubTime":"2021-12-08 13:37","market":"us","language":"en","title":"Goldman Sachs Has Bad News for Investors Rushing to Buy the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2189163737","media":"Bloomberg","summary":"(Bloomberg) -- Goldman Sachs Group Inc. is issuing words of caution for dip buyers plunging back int","content":"<p>(Bloomberg) -- Goldman Sachs Group Inc. is issuing words of caution for dip buyers plunging back into stocks: The December volatility breakout has room to run -- and risk gauges aren’t yet flashing buy signals.</p>\n<p>The hawkish tilt from the Federal Reserve just as the omicron variant spreads will continue to create all manner of trading challenges in the near-term, according to Christian Mueller-Glissmann, managing director of portfolio strategy and asset allocation at the firm.</p>\n<p>After a selling wave that brought down everything from big tech to Bitcoin, the Goldman Sachs Risk Appetite Indicator is below zero, but it could still fall farther, according to the firm.</p>\n<p>“Without any view on better macro you would want the RAI closer to -2 before adding risk,” said Mueller-Glissmann in an interview. “A drop below or near -2 could create a very good opportunity to re-risk and position more procyclical, especially if growth stabilizes post-omicron.”</p>\n<p>His caution contrasts with a big turnaround in risk assets this week on signs the new strain won’t be as virulent and deadly as feared and won’t drive the economic recovery off-course.</p>\n<p>Meanwhile, a Deutsche Bank AG gauge signals risk assets may be closing in on a bottom.</p>\n<p>Volatility markets show fragile sentiment. Investors are paying up to hedge against wilder swings than what they’ve experienced already. Last week’s run of turbulence was the worst in a year, with the S&amp;P 500 notching up or down moves of at least 1% on five straight days through Friday.</p>\n<p>At 27, the VIX still sits seven points above its average for the year and the front-month futures contract is higher than ones in subsequent months, a signal that investors anticipate near-term turbulence to persist.</p>\n<p>All the same, a Deutsche Bank cross-asset momentum measure is firmly negative and already near historic lows.</p>\n<p>“The breadth is now approaching a place where it does usually turn around so we’ll expect some asset classes to find a bottom here,” Parag Thatte, strategist at Deutsche Bank, said in an interview. “The turnaround should be in the short term, it should be in the next three-four weeks.”</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman Sachs Has Bad News for Investors Rushing to Buy the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman Sachs Has Bad News for Investors Rushing to Buy the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 13:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/goldman-sachs-bad-news-investors-140022485.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Goldman Sachs Group Inc. is issuing words of caution for dip buyers plunging back into stocks: The December volatility breakout has room to run -- and risk gauges aren’t yet flashing ...</p>\n\n<a href=\"https://finance.yahoo.com/news/goldman-sachs-bad-news-investors-140022485.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4211":"区域性银行","BK4552":"Archegos爆仓风波概念",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4127":"投资银行业与经纪业","BK4111":"出版","GS":"高盛","BK4504":"桥水持仓",".SPX":"S&P 500 Index","BK4550":"红杉资本持仓"},"source_url":"https://finance.yahoo.com/news/goldman-sachs-bad-news-investors-140022485.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2189163737","content_text":"(Bloomberg) -- Goldman Sachs Group Inc. is issuing words of caution for dip buyers plunging back into stocks: The December volatility breakout has room to run -- and risk gauges aren’t yet flashing buy signals.\nThe hawkish tilt from the Federal Reserve just as the omicron variant spreads will continue to create all manner of trading challenges in the near-term, according to Christian Mueller-Glissmann, managing director of portfolio strategy and asset allocation at the firm.\nAfter a selling wave that brought down everything from big tech to Bitcoin, the Goldman Sachs Risk Appetite Indicator is below zero, but it could still fall farther, according to the firm.\n“Without any view on better macro you would want the RAI closer to -2 before adding risk,” said Mueller-Glissmann in an interview. “A drop below or near -2 could create a very good opportunity to re-risk and position more procyclical, especially if growth stabilizes post-omicron.”\nHis caution contrasts with a big turnaround in risk assets this week on signs the new strain won’t be as virulent and deadly as feared and won’t drive the economic recovery off-course.\nMeanwhile, a Deutsche Bank AG gauge signals risk assets may be closing in on a bottom.\nVolatility markets show fragile sentiment. Investors are paying up to hedge against wilder swings than what they’ve experienced already. Last week’s run of turbulence was the worst in a year, with the S&P 500 notching up or down moves of at least 1% on five straight days through Friday.\nAt 27, the VIX still sits seven points above its average for the year and the front-month futures contract is higher than ones in subsequent months, a signal that investors anticipate near-term turbulence to persist.\nAll the same, a Deutsche Bank cross-asset momentum measure is firmly negative and already near historic lows.\n“The breadth is now approaching a place where it does usually turn around so we’ll expect some asset classes to find a bottom here,” Parag Thatte, strategist at Deutsche Bank, said in an interview. “The turnaround should be in the short term, it should be in the next three-four weeks.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606366281,"gmtCreate":1638836060644,"gmtModify":1638836061265,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Santa claus is coming to town..time to do some shopping!","listText":"Santa claus is coming to town..time to do some shopping!","text":"Santa claus is coming to town..time to do some shopping!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606366281","repostId":"1109373311","repostType":4,"repost":{"id":"1109373311","pubTimestamp":1638835203,"share":"https://www.laohu8.com/m/news/1109373311?lang=&edition=full","pubTime":"2021-12-07 08:00","market":"us","language":"en","title":"Speedy Dip-Buying Mini S&P Corrections Has Become a Market Habit","url":"https://stock-news.laohu8.com/highlight/detail?id=1109373311","media":"Bloomberg","summary":"The S&P 500 Index hasn’t had a technical correction of 10% or more in 2021. Instead, more frequent s","content":"<p>The S&amp;P 500 Index hasn’t had a technical correction of 10% or more in 2021. Instead, more frequent shallow pullbacks of 4% to 5% have become the norm -- followed by quick rallies.</p>\n<p>The speed of the bounce-backs is noteworthy, taking almost half the time to recover lost gains than the drop itself. Today’s Chart of the Day illustrates the dynamic on a logarithmic scale. In essence, the dips are being bought at a faster rate than the historical norm.</p>\n<p><img src=\"https://static.tigerbbs.com/9929442e27e5f3ab09853c152b77367e\" tg-width=\"930\" tg-height=\"523\" referrerpolicy=\"no-referrer\"></p>\n<p>Historically, recovering gains from pullbacks or corrections has tended to take at least as long as the drop itself. Markets haven’t seen this pace of dip-buying since 2016, which marked the beginning of two years of coordinated global growth until the trade war between the U.S. and China roiled financial markets in 2018.</p>\n<p>A similar dynamic is visible now, with every region of the world simultaneously seeing consumption and production rise relative to last year at the same time. Recovering from a halted global economy is creating surging demand, something that’s arguably being reflected in the U.S. stock market.</p>\n<p>It’s almost reminiscent of the historically speedy recovery that followed the March 2020 bear market, which only took five months to regain the losses as mega-cap tech led the way. Indeed, the same handful of companies have been leading the relief rallies in 2021 following these pullbacks -- and creating 66 record highs for the S&amp;P 500.</p>\n<p>Looking at recent price action, the S&amp;P 500 has had a maximum drawdown of 4.1% since Black Friday on Nov. 26, amid thinner trading. December tends to have lighter trading volume than the rest of the year as Wall Street equity desks slouch into the holiday season. Ordinarily, this leads to a “Santa Rally” in the benchmark. But investors are wondering if that will materialize this year this time, with markets fearing tighter monetary policy on the horizon.</p>\n<p><img src=\"https://static.tigerbbs.com/e7a4370741884dbc5fc7fb557d016295\" tg-width=\"930\" tg-height=\"523\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Speedy Dip-Buying Mini S&P Corrections Has Become a Market Habit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpeedy Dip-Buying Mini S&P Corrections Has Become a Market Habit\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 08:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-06/speedy-dip-buying-mini-s-p-corrections-has-become-a-market-habit><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 Index hasn’t had a technical correction of 10% or more in 2021. Instead, more frequent shallow pullbacks of 4% to 5% have become the norm -- followed by quick rallies.\nThe speed of the ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-06/speedy-dip-buying-mini-s-p-corrections-has-become-a-market-habit\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index"},"source_url":"https://www.bloomberg.com/news/articles/2021-12-06/speedy-dip-buying-mini-s-p-corrections-has-become-a-market-habit","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109373311","content_text":"The S&P 500 Index hasn’t had a technical correction of 10% or more in 2021. Instead, more frequent shallow pullbacks of 4% to 5% have become the norm -- followed by quick rallies.\nThe speed of the bounce-backs is noteworthy, taking almost half the time to recover lost gains than the drop itself. Today’s Chart of the Day illustrates the dynamic on a logarithmic scale. In essence, the dips are being bought at a faster rate than the historical norm.\n\nHistorically, recovering gains from pullbacks or corrections has tended to take at least as long as the drop itself. Markets haven’t seen this pace of dip-buying since 2016, which marked the beginning of two years of coordinated global growth until the trade war between the U.S. and China roiled financial markets in 2018.\nA similar dynamic is visible now, with every region of the world simultaneously seeing consumption and production rise relative to last year at the same time. Recovering from a halted global economy is creating surging demand, something that’s arguably being reflected in the U.S. stock market.\nIt’s almost reminiscent of the historically speedy recovery that followed the March 2020 bear market, which only took five months to regain the losses as mega-cap tech led the way. Indeed, the same handful of companies have been leading the relief rallies in 2021 following these pullbacks -- and creating 66 record highs for the S&P 500.\nLooking at recent price action, the S&P 500 has had a maximum drawdown of 4.1% since Black Friday on Nov. 26, amid thinner trading. December tends to have lighter trading volume than the rest of the year as Wall Street equity desks slouch into the holiday season. Ordinarily, this leads to a “Santa Rally” in the benchmark. But investors are wondering if that will materialize this year this time, with markets fearing tighter monetary policy on the horizon.","news_type":1},"isVote":1,"tweetType":1,"viewCount":231,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608221459,"gmtCreate":1638750830151,"gmtModify":1638750830460,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Lost the magic&nbsp;touch? Let's observe few more quarters.","listText":"Lost the magic&nbsp;touch? Let's observe few more quarters.","text":"Lost the magic touch? Let's observe few more quarters.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608221459","repostId":"2189957413","repostType":2,"repost":{"id":"2189957413","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1638746998,"share":"https://www.laohu8.com/m/news/2189957413?lang=&edition=full","pubTime":"2021-12-06 07:29","market":"us","language":"en","title":"Disney's 'Encanto' Leads Another Quiet Weekend at Box Office","url":"https://stock-news.laohu8.com/highlight/detail?id=2189957413","media":"Reuters","summary":"LOS ANGELES, Dec 5 (Variety.com) - Without any new releases to pose a threat, Disney's animated musi","content":"<p>LOS ANGELES, Dec 5 (Variety.com) - Without any new releases to pose a threat, Disney's animated musical fable \"Encanto\" has again notched the No. 1 spot on domestic box office charts.</p>\n<p>In its second weekend of release, \"Encanto\" has collected $12.38 million from 3,980 venues in the U.S. and Canada. That marks a 54% drop from its debut and pushes the film's two-week total to $57.6 million domestically.</p>\n<p>A decline of roughly 50% between its first and second weekend is in line with Disney's recent Thanksgiving releases, such as 2016's \"Moana\" (down 50%), 2017's \"Coco\" (down only 45%) 2018's \"Ralph Breaks the Internet\" (down 54%) and 2019's \"Frozen II\" (down 59%). Prior Disney animated features were able to conjure stronger starts at the domestic box office, however, those films weren't playing in theaters during a pandemic. By COVID-19 standards, \"Encanto\" is faring well at the box office. The family-friendly adventure, which boasts songs by \"Hamilton\" creator Lin-Manuel Miranda, will land on Disney Plus after playing exclusively in theaters for 30 days.</p>\n<p>Other than \"Encanto\" and its fellow holdover titles, like MGM's starry crime drama \"House of Gucci\" and Sony's \"Ghostbusters: Afterlife\" reboot, it's all quiet on the box office front. That is, until Steven Spielberg's marvelously received \"West Side Story\" adaptation lands in theaters on Dec. 10 and Tom Holland's comic book adventure \"Spider-Man: No Way Home\" hits the big screen on Dec. 17.</p>\n<p>Although big-budget films have started to return to cinemas and COVID-19 vaccines have been approved for younger children, movie theater attendance has remained on the lighter side. Still, Hollywood studios and film exhibitors have been optimistic that Spielberg's latest, Spidey's finale and Neo's return in \"The Matrix: Resurrections\" on Dec. 22 will be a potent enough combination to boost ticket sales in December.</p>\n<p>Until then, theater operators will be serving up leftovers. The domestic box office chart's standings are near identical to last weekend's results, with \"Ghostbusters: Afterlife\" in second place, \"House of Gucci\" at No. 3 and Marvel's comic book epic \"Eternals\" in fifth place.</p>\n<p>Fourth place was won by Fathom Events' \"Christmas With the Chosen: The Messengers.\" The release is a holiday special of the religious streaming series \"The Chosen\" and recounts the birth and life of Jesus Christ. \"The Messengers\" is projected to earn $4 million over the three-day weekend. Fathom Events sold $1.5 million in pre-sales during its first 12 hours of availability, prompting an expansion to a 10-night run across 1,700 theaters, the largest in the history of the specialty distributor.</p>\n<p>\"Afterlife,\" in its third weekend of release, collected $10.35 million from 4,059 North American theaters. In a notable pandemic-era milestone, the film is set to surpass $100 million domestically on Sunday. \"Afterlife,\" which is available only in theaters, will have generated an impressive $101 million to date once the weekend ends.</p>\n<p>Elsewhere, Lady Gaga continues to prop up the movie theater business. Her latest film \"House of Gucci\" added $6.77 million from 3,477 locations in the U.S. and Canada. After debuting to $21 million over the extended Thanksgiving holiday weekend, \"House of Gucci\" has boosted its domestic tally to $33.6 million, which isn't a bad result at a time when most adult dramas during the pandemic have struggled to reach $10 million in total. But decent box office receipts by COVID-19 standards may not be enough to ensure \"House of Gucci\" becomes profitable. Since it cost $75 million to produce and many millions more to advertise, \"House of Gucci\" will need international audiences to turn out in force to get the movie out of the red.</p>\n<p>After five weeks in theaters, \"Eternals\" brought in $3.8 million from 3,230 cinemas this weekend. The comic book adaptation -- starring Gemma Chan, Richard Madden, Kumail Nanjiani, Salma Hayek and Angelina Jolie -- has amassed $156 million at the domestic box office -- an impressive number, albeit <a href=\"https://laohu8.com/S/AONE.U\">one</a> that's a little beneath Marvel's usual sky-high performances.</p>\n<p>Also notable is Warner Bros. and Legendary's \"Dune,\" which returned to IMAX screens this weekend for a final dance with premium formats at the tail end of its theatrical run. The Denis Villeneuve-helmed sci-fi epic experienced a measly drop of 16% from the Thanksgiving holiday.</p>\n<p>Over in the world of independent releases, MGM and United Artists Releasing's \"Licorice Pizza\" continued to draw audiences in its limited four-location engagement. The latest from Paul Thomas Anderson grossed $223,000 in its second weekend, marking a slight dip of 35% from its debut last week. The film landed pandemic-best numbers for per-theater average in its opening.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disney's 'Encanto' Leads Another Quiet Weekend at Box Office</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisney's 'Encanto' Leads Another Quiet Weekend at Box Office\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-06 07:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LOS ANGELES, Dec 5 (Variety.com) - Without any new releases to pose a threat, Disney's animated musical fable \"Encanto\" has again notched the No. 1 spot on domestic box office charts.</p>\n<p>In its second weekend of release, \"Encanto\" has collected $12.38 million from 3,980 venues in the U.S. and Canada. That marks a 54% drop from its debut and pushes the film's two-week total to $57.6 million domestically.</p>\n<p>A decline of roughly 50% between its first and second weekend is in line with Disney's recent Thanksgiving releases, such as 2016's \"Moana\" (down 50%), 2017's \"Coco\" (down only 45%) 2018's \"Ralph Breaks the Internet\" (down 54%) and 2019's \"Frozen II\" (down 59%). Prior Disney animated features were able to conjure stronger starts at the domestic box office, however, those films weren't playing in theaters during a pandemic. By COVID-19 standards, \"Encanto\" is faring well at the box office. The family-friendly adventure, which boasts songs by \"Hamilton\" creator Lin-Manuel Miranda, will land on Disney Plus after playing exclusively in theaters for 30 days.</p>\n<p>Other than \"Encanto\" and its fellow holdover titles, like MGM's starry crime drama \"House of Gucci\" and Sony's \"Ghostbusters: Afterlife\" reboot, it's all quiet on the box office front. That is, until Steven Spielberg's marvelously received \"West Side Story\" adaptation lands in theaters on Dec. 10 and Tom Holland's comic book adventure \"Spider-Man: No Way Home\" hits the big screen on Dec. 17.</p>\n<p>Although big-budget films have started to return to cinemas and COVID-19 vaccines have been approved for younger children, movie theater attendance has remained on the lighter side. Still, Hollywood studios and film exhibitors have been optimistic that Spielberg's latest, Spidey's finale and Neo's return in \"The Matrix: Resurrections\" on Dec. 22 will be a potent enough combination to boost ticket sales in December.</p>\n<p>Until then, theater operators will be serving up leftovers. The domestic box office chart's standings are near identical to last weekend's results, with \"Ghostbusters: Afterlife\" in second place, \"House of Gucci\" at No. 3 and Marvel's comic book epic \"Eternals\" in fifth place.</p>\n<p>Fourth place was won by Fathom Events' \"Christmas With the Chosen: The Messengers.\" The release is a holiday special of the religious streaming series \"The Chosen\" and recounts the birth and life of Jesus Christ. \"The Messengers\" is projected to earn $4 million over the three-day weekend. Fathom Events sold $1.5 million in pre-sales during its first 12 hours of availability, prompting an expansion to a 10-night run across 1,700 theaters, the largest in the history of the specialty distributor.</p>\n<p>\"Afterlife,\" in its third weekend of release, collected $10.35 million from 4,059 North American theaters. In a notable pandemic-era milestone, the film is set to surpass $100 million domestically on Sunday. \"Afterlife,\" which is available only in theaters, will have generated an impressive $101 million to date once the weekend ends.</p>\n<p>Elsewhere, Lady Gaga continues to prop up the movie theater business. Her latest film \"House of Gucci\" added $6.77 million from 3,477 locations in the U.S. and Canada. After debuting to $21 million over the extended Thanksgiving holiday weekend, \"House of Gucci\" has boosted its domestic tally to $33.6 million, which isn't a bad result at a time when most adult dramas during the pandemic have struggled to reach $10 million in total. But decent box office receipts by COVID-19 standards may not be enough to ensure \"House of Gucci\" becomes profitable. Since it cost $75 million to produce and many millions more to advertise, \"House of Gucci\" will need international audiences to turn out in force to get the movie out of the red.</p>\n<p>After five weeks in theaters, \"Eternals\" brought in $3.8 million from 3,230 cinemas this weekend. The comic book adaptation -- starring Gemma Chan, Richard Madden, Kumail Nanjiani, Salma Hayek and Angelina Jolie -- has amassed $156 million at the domestic box office -- an impressive number, albeit <a href=\"https://laohu8.com/S/AONE.U\">one</a> that's a little beneath Marvel's usual sky-high performances.</p>\n<p>Also notable is Warner Bros. and Legendary's \"Dune,\" which returned to IMAX screens this weekend for a final dance with premium formats at the tail end of its theatrical run. The Denis Villeneuve-helmed sci-fi epic experienced a measly drop of 16% from the Thanksgiving holiday.</p>\n<p>Over in the world of independent releases, MGM and United Artists Releasing's \"Licorice Pizza\" continued to draw audiences in its limited four-location engagement. The latest from Paul Thomas Anderson grossed $223,000 in its second weekend, marking a slight dip of 35% from its debut last week. The film landed pandemic-best numbers for per-theater average in its opening.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIS":"迪士尼"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189957413","content_text":"LOS ANGELES, Dec 5 (Variety.com) - Without any new releases to pose a threat, Disney's animated musical fable \"Encanto\" has again notched the No. 1 spot on domestic box office charts.\nIn its second weekend of release, \"Encanto\" has collected $12.38 million from 3,980 venues in the U.S. and Canada. That marks a 54% drop from its debut and pushes the film's two-week total to $57.6 million domestically.\nA decline of roughly 50% between its first and second weekend is in line with Disney's recent Thanksgiving releases, such as 2016's \"Moana\" (down 50%), 2017's \"Coco\" (down only 45%) 2018's \"Ralph Breaks the Internet\" (down 54%) and 2019's \"Frozen II\" (down 59%). Prior Disney animated features were able to conjure stronger starts at the domestic box office, however, those films weren't playing in theaters during a pandemic. By COVID-19 standards, \"Encanto\" is faring well at the box office. The family-friendly adventure, which boasts songs by \"Hamilton\" creator Lin-Manuel Miranda, will land on Disney Plus after playing exclusively in theaters for 30 days.\nOther than \"Encanto\" and its fellow holdover titles, like MGM's starry crime drama \"House of Gucci\" and Sony's \"Ghostbusters: Afterlife\" reboot, it's all quiet on the box office front. That is, until Steven Spielberg's marvelously received \"West Side Story\" adaptation lands in theaters on Dec. 10 and Tom Holland's comic book adventure \"Spider-Man: No Way Home\" hits the big screen on Dec. 17.\nAlthough big-budget films have started to return to cinemas and COVID-19 vaccines have been approved for younger children, movie theater attendance has remained on the lighter side. Still, Hollywood studios and film exhibitors have been optimistic that Spielberg's latest, Spidey's finale and Neo's return in \"The Matrix: Resurrections\" on Dec. 22 will be a potent enough combination to boost ticket sales in December.\nUntil then, theater operators will be serving up leftovers. The domestic box office chart's standings are near identical to last weekend's results, with \"Ghostbusters: Afterlife\" in second place, \"House of Gucci\" at No. 3 and Marvel's comic book epic \"Eternals\" in fifth place.\nFourth place was won by Fathom Events' \"Christmas With the Chosen: The Messengers.\" The release is a holiday special of the religious streaming series \"The Chosen\" and recounts the birth and life of Jesus Christ. \"The Messengers\" is projected to earn $4 million over the three-day weekend. Fathom Events sold $1.5 million in pre-sales during its first 12 hours of availability, prompting an expansion to a 10-night run across 1,700 theaters, the largest in the history of the specialty distributor.\n\"Afterlife,\" in its third weekend of release, collected $10.35 million from 4,059 North American theaters. In a notable pandemic-era milestone, the film is set to surpass $100 million domestically on Sunday. \"Afterlife,\" which is available only in theaters, will have generated an impressive $101 million to date once the weekend ends.\nElsewhere, Lady Gaga continues to prop up the movie theater business. Her latest film \"House of Gucci\" added $6.77 million from 3,477 locations in the U.S. and Canada. After debuting to $21 million over the extended Thanksgiving holiday weekend, \"House of Gucci\" has boosted its domestic tally to $33.6 million, which isn't a bad result at a time when most adult dramas during the pandemic have struggled to reach $10 million in total. But decent box office receipts by COVID-19 standards may not be enough to ensure \"House of Gucci\" becomes profitable. Since it cost $75 million to produce and many millions more to advertise, \"House of Gucci\" will need international audiences to turn out in force to get the movie out of the red.\nAfter five weeks in theaters, \"Eternals\" brought in $3.8 million from 3,230 cinemas this weekend. The comic book adaptation -- starring Gemma Chan, Richard Madden, Kumail Nanjiani, Salma Hayek and Angelina Jolie -- has amassed $156 million at the domestic box office -- an impressive number, albeit one that's a little beneath Marvel's usual sky-high performances.\nAlso notable is Warner Bros. and Legendary's \"Dune,\" which returned to IMAX screens this weekend for a final dance with premium formats at the tail end of its theatrical run. The Denis Villeneuve-helmed sci-fi epic experienced a measly drop of 16% from the Thanksgiving holiday.\nOver in the world of independent releases, MGM and United Artists Releasing's \"Licorice Pizza\" continued to draw audiences in its limited four-location engagement. The latest from Paul Thomas Anderson grossed $223,000 in its second weekend, marking a slight dip of 35% from its debut last week. The film landed pandemic-best numbers for per-theater average in its opening.","news_type":1},"isVote":1,"tweetType":1,"viewCount":321,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608264992,"gmtCreate":1638750268356,"gmtModify":1638750268659,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"I guess we already get used to this...","listText":"I guess we already get used to this...","text":"I guess we already get used to this...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608264992","repostId":"2188576467","repostType":2,"repost":{"id":"2188576467","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1638748562,"share":"https://www.laohu8.com/m/news/2188576467?lang=&edition=full","pubTime":"2021-12-06 07:56","market":"us","language":"en","title":"Goldman Sachs cuts U.S. GDP growth forecast for 2022 over Omicron fears","url":"https://stock-news.laohu8.com/highlight/detail?id=2188576467","media":"Reuters","summary":"Dec 4 (Reuters) - Goldman Sachs on Saturday cut its outlook for U.S. economic growth to 3.8% for 202","content":"<p>Dec 4 (Reuters) - Goldman Sachs on Saturday cut its outlook for U.S. economic growth to 3.8% for 2022, citing risks and uncertainty around the emergence of the Omicron variant of the coronavirus.</p>\n<p>Goldman economist Joseph Briggs said in a note that the Omicron variant could slow economic reopening, but the firm expects \"only a modest drag\" on service spending.</p>\n<p>The firm now sees 2022 gross domestic product <a href=\"https://laohu8.com/S/GDP\">$(GDP)$</a> growth of 3.8%, down from 4.2% previously on a full year basis, and Q4/Q4 growth of 2.9%, down from 3.3% before, Briggs said.</p>\n<p>\"While many questions remain unanswered, we now think a moderate downside scenario where the virus spreads more quickly but immunity against severe disease is only slightly weakened is most likely,\" he said.</p>\n<p>Worker shortages could last longer if people do not feel comfortable returning to work due to the variant, according to the note.</p>\n<p>Goldman pointed the spread of the virus could worsen supply shortages should other countries implement tighter restrictions, but increase in vaccination rates among foreign trade partners would prevent severe disruptions.</p>\n<p>Goldman Sachs' U.S. forecast comes after the International Monetary Fund Managing Director Kristalina Georgieva said on Friday that the lender was likely to lower its global economic growth estimates due to the new Omicron variant of the coronavirus.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman Sachs cuts U.S. GDP growth forecast for 2022 over Omicron fears</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman Sachs cuts U.S. GDP growth forecast for 2022 over Omicron fears\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-06 07:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 4 (Reuters) - Goldman Sachs on Saturday cut its outlook for U.S. economic growth to 3.8% for 2022, citing risks and uncertainty around the emergence of the Omicron variant of the coronavirus.</p>\n<p>Goldman economist Joseph Briggs said in a note that the Omicron variant could slow economic reopening, but the firm expects \"only a modest drag\" on service spending.</p>\n<p>The firm now sees 2022 gross domestic product <a href=\"https://laohu8.com/S/GDP\">$(GDP)$</a> growth of 3.8%, down from 4.2% previously on a full year basis, and Q4/Q4 growth of 2.9%, down from 3.3% before, Briggs said.</p>\n<p>\"While many questions remain unanswered, we now think a moderate downside scenario where the virus spreads more quickly but immunity against severe disease is only slightly weakened is most likely,\" he said.</p>\n<p>Worker shortages could last longer if people do not feel comfortable returning to work due to the variant, according to the note.</p>\n<p>Goldman pointed the spread of the virus could worsen supply shortages should other countries implement tighter restrictions, but increase in vaccination rates among foreign trade partners would prevent severe disruptions.</p>\n<p>Goldman Sachs' U.S. forecast comes after the International Monetary Fund Managing Director Kristalina Georgieva said on Friday that the lender was likely to lower its global economic growth estimates due to the new Omicron variant of the coronavirus.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","GS":"高盛","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4504":"桥水持仓","BK4552":"Archegos爆仓风波概念"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188576467","content_text":"Dec 4 (Reuters) - Goldman Sachs on Saturday cut its outlook for U.S. economic growth to 3.8% for 2022, citing risks and uncertainty around the emergence of the Omicron variant of the coronavirus.\nGoldman economist Joseph Briggs said in a note that the Omicron variant could slow economic reopening, but the firm expects \"only a modest drag\" on service spending.\nThe firm now sees 2022 gross domestic product $(GDP)$ growth of 3.8%, down from 4.2% previously on a full year basis, and Q4/Q4 growth of 2.9%, down from 3.3% before, Briggs said.\n\"While many questions remain unanswered, we now think a moderate downside scenario where the virus spreads more quickly but immunity against severe disease is only slightly weakened is most likely,\" he said.\nWorker shortages could last longer if people do not feel comfortable returning to work due to the variant, according to the note.\nGoldman pointed the spread of the virus could worsen supply shortages should other countries implement tighter restrictions, but increase in vaccination rates among foreign trade partners would prevent severe disruptions.\nGoldman Sachs' U.S. forecast comes after the International Monetary Fund Managing Director Kristalina Georgieva said on Friday that the lender was likely to lower its global economic growth estimates due to the new Omicron variant of the coronavirus.","news_type":1},"isVote":1,"tweetType":1,"viewCount":277,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608320359,"gmtCreate":1638630586548,"gmtModify":1638630586891,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"HODL!","listText":"HODL!","text":"HODL!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608320359","repostId":"1140678193","repostType":4,"isVote":1,"tweetType":1,"viewCount":396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609960471,"gmtCreate":1638232074868,"gmtModify":1638232750092,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Bought some to keep!","listText":"Bought some to keep!","text":"Bought some to keep!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609960471","repostId":"1195739083","repostType":4,"repost":{"id":"1195739083","pubTimestamp":1638184010,"share":"https://www.laohu8.com/m/news/1195739083?lang=&edition=full","pubTime":"2021-11-29 19:06","market":"us","language":"en","title":"Will This Beaten-Down Stock Bounce Back? 3 Things to Know","url":"https://stock-news.laohu8.com/highlight/detail?id=1195739083","media":"Motley Fool","summary":"All the elements are in place for a rebound.","content":"<p><b>Vertex Pharmaceuticals</b>(NASDAQ:VRTX)&nbsp;has given more than one investor a headache over the past year. The company's shares have suffered ever since the company announced the failure of two candidates -- one in October 2020 and one this spring -- in clinical trials. They've dropped more than 30% since the first failure. Investors worry that Vertex is struggling to expand beyond its core portfolio of cystic fibrosis (CF) treatments.</p>\n<p>Considering the time Vertex shares have spent in the doldrums, you may be getting a little impatient. In fact, you may be wondering: Will this beaten-down stock ever will recover? Before answering, here are three things to know.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/35efdfa23680ecdc2c35cfd21dcba413\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>1. CF may bring in billions for a long while</b></p>\n<p>As I mentioned, investors' one big concern right now is about Vertex's ability to develop drugs beyond its core program. That's understandable. But it's important to put the concern into perspective. Let's consider the revenue CF treatments generate for Vertex, its market share, and how long it's likely to maintain its position in the market.</p>\n<p>CF treatments generate billions in revenue and profit for Vertex.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1a492d9390c7d692f0b6b85ff9388d6f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>VRTX Net Income (Annual) data by YCharts</span></p>\n<p>The company is the global CF treatment market leader. In fact, the only up-and-coming treatment that may threaten its latest blockbuster Trikafta is another candidate in Vertex's pipeline. The company recently launched a phase 3 trial of that candidate. And Vertex said last year that it expects to maintain market leadership until at least the late 2030s.</p>\n<p>All of this means that Vertex isn't about to see revenue fall any time soon. So, if it takes Vertex time to reach commercialization with non-CF programs, that's OK.</p>\n<p>2. Two pipeline candidates could be gamechangers</p>\n<p>Vertex is making progress in several areas beyond CF. The company is studying candidates in seven other treatment areas. Two candidates in particular have caught my eye: a treatment for blood disorders and a therapy for type 1 diabetes (T1D).</p>\n<p>Let's start with CTX001 for blood disorders. The company has reported positive trial results in both beta thalassemia and sickle cell disease. If all continues to go well, Vertex and partner&nbsp;<b>CRISPR Therapeutics</b>&nbsp;plan to file for regulatory approval by the end of next year. The potential product could be a gamechanger because it is a designed as a one-time curative&nbsp;treatment. Today, treatment options for these disorders are limited.</p>\n<p>Farther down the road, Vertex's T1D candidate could become another key product. Treatment options for T1D pretty much boil down to administering insulin. Vertex's candidate is a stem-cell derived therapy that is meant to actually restore the body's ability to produce insulin. It did so in the first patient in a phase 1/2 trial.</p>\n<p>Both of these potential products could be significant for Vertex -- and add billions to revenue.</p>\n<p><b>3. At today's level, Vertex is a bargain</b></p>\n<p>Vertex is trading at its lowest in relation to forward earnings estimates since at least the start of last year.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9a33e676553135e9cc6a3fe0e0123498\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>VRTX PE Ratio (Forward) data by YCharts</span></p>\n<p>This looks like a bargain considering the strength of Vertex's CF portfolio and the company's potential products on the horizon. In the worst scenario, Vertex may continue to bring in billions of dollars in revenue from the CF program -- but take a while to bring a non-CF product to market. In the best scenario, Vertex could generate revenue from a non-CF blockbuster -- CXT001 -- as early as in 2023. This is considering a late 2022 regulatory filing and six to 10 months review time. And that's on top of CF product revenue growth.</p>\n<p>In either case, Vertex today is looking inexpensive.</p>\n<p><b>So, will Vertex bounce back?</b></p>\n<p>Of course, no one can say for sure if Vertex shares will climb. But the company has the elements necessary for a rebound -- and eventual gains. I'm talking about blockbuster revenue and market leadership well into the future, and&nbsp;promising candidates&nbsp;in the pipeline. These factors are key to driving a biotech stock higher over time.</p>\n<p>I'm not expecting Vertex's rebound to happen overnight. The clinical trial failures seriously shook investor confidence. But if Vertex announces more and more&nbsp;positive news&nbsp;from its blood disorders and T1D programs, it has a strong chance of winning that confidence back.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will This Beaten-Down Stock Bounce Back? 3 Things to Know</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill This Beaten-Down Stock Bounce Back? 3 Things to Know\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 19:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/29/will-this-beaten-down-stock-bounce-back/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vertex Pharmaceuticals(NASDAQ:VRTX) has given more than one investor a headache over the past year. The company's shares have suffered ever since the company announced the failure of two candidates --...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/29/will-this-beaten-down-stock-bounce-back/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/11/29/will-this-beaten-down-stock-bounce-back/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195739083","content_text":"Vertex Pharmaceuticals(NASDAQ:VRTX) has given more than one investor a headache over the past year. The company's shares have suffered ever since the company announced the failure of two candidates -- one in October 2020 and one this spring -- in clinical trials. They've dropped more than 30% since the first failure. Investors worry that Vertex is struggling to expand beyond its core portfolio of cystic fibrosis (CF) treatments.\nConsidering the time Vertex shares have spent in the doldrums, you may be getting a little impatient. In fact, you may be wondering: Will this beaten-down stock ever will recover? Before answering, here are three things to know.\nIMAGE SOURCE: GETTY IMAGES.\n1. CF may bring in billions for a long while\nAs I mentioned, investors' one big concern right now is about Vertex's ability to develop drugs beyond its core program. That's understandable. But it's important to put the concern into perspective. Let's consider the revenue CF treatments generate for Vertex, its market share, and how long it's likely to maintain its position in the market.\nCF treatments generate billions in revenue and profit for Vertex.\nVRTX Net Income (Annual) data by YCharts\nThe company is the global CF treatment market leader. In fact, the only up-and-coming treatment that may threaten its latest blockbuster Trikafta is another candidate in Vertex's pipeline. The company recently launched a phase 3 trial of that candidate. And Vertex said last year that it expects to maintain market leadership until at least the late 2030s.\nAll of this means that Vertex isn't about to see revenue fall any time soon. So, if it takes Vertex time to reach commercialization with non-CF programs, that's OK.\n2. Two pipeline candidates could be gamechangers\nVertex is making progress in several areas beyond CF. The company is studying candidates in seven other treatment areas. Two candidates in particular have caught my eye: a treatment for blood disorders and a therapy for type 1 diabetes (T1D).\nLet's start with CTX001 for blood disorders. The company has reported positive trial results in both beta thalassemia and sickle cell disease. If all continues to go well, Vertex and partner CRISPR Therapeutics plan to file for regulatory approval by the end of next year. The potential product could be a gamechanger because it is a designed as a one-time curative treatment. Today, treatment options for these disorders are limited.\nFarther down the road, Vertex's T1D candidate could become another key product. Treatment options for T1D pretty much boil down to administering insulin. Vertex's candidate is a stem-cell derived therapy that is meant to actually restore the body's ability to produce insulin. It did so in the first patient in a phase 1/2 trial.\nBoth of these potential products could be significant for Vertex -- and add billions to revenue.\n3. At today's level, Vertex is a bargain\nVertex is trading at its lowest in relation to forward earnings estimates since at least the start of last year.\nVRTX PE Ratio (Forward) data by YCharts\nThis looks like a bargain considering the strength of Vertex's CF portfolio and the company's potential products on the horizon. In the worst scenario, Vertex may continue to bring in billions of dollars in revenue from the CF program -- but take a while to bring a non-CF product to market. In the best scenario, Vertex could generate revenue from a non-CF blockbuster -- CXT001 -- as early as in 2023. This is considering a late 2022 regulatory filing and six to 10 months review time. And that's on top of CF product revenue growth.\nIn either case, Vertex today is looking inexpensive.\nSo, will Vertex bounce back?\nOf course, no one can say for sure if Vertex shares will climb. But the company has the elements necessary for a rebound -- and eventual gains. I'm talking about blockbuster revenue and market leadership well into the future, and promising candidates in the pipeline. These factors are key to driving a biotech stock higher over time.\nI'm not expecting Vertex's rebound to happen overnight. The clinical trial failures seriously shook investor confidence. But if Vertex announces more and more positive news from its blood disorders and T1D programs, it has a strong chance of winning that confidence back.","news_type":1},"isVote":1,"tweetType":1,"viewCount":194,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874595132,"gmtCreate":1637799419457,"gmtModify":1637800619846,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"In the future, without the internet we can literally do nothing...good or bad?","listText":"In the future, without the internet we can literally do nothing...good or bad?","text":"In the future, without the internet we can literally do nothing...good or bad?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874595132","repostId":"2186436615","repostType":4,"isVote":1,"tweetType":1,"viewCount":400,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":147635075,"gmtCreate":1626355645997,"gmtModify":1633927586384,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"We call this correction, let's see will it happen..[真香]&nbsp;[真香]&nbsp;","listText":"We call this correction, let's see will it happen..[真香]&nbsp;[真香]&nbsp;","text":"We call this correction, let's see will it happen..[真香] [真香]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/147635075","repostId":"2151269095","repostType":4,"isVote":1,"tweetType":1,"viewCount":30,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862630531,"gmtCreate":1632874283260,"gmtModify":1632874283534,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Is V joining the party soon?","listText":"Is V joining the party soon?","text":"Is V joining the party soon?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/862630531","repostId":"1170196264","repostType":2,"repost":{"id":"1170196264","pubTimestamp":1632873371,"share":"https://www.laohu8.com/m/news/1170196264?lang=&edition=full","pubTime":"2021-09-29 07:56","market":"us","language":"en","title":"Every High-Growth Investor Must Keep This Huge Threat in Mind","url":"https://stock-news.laohu8.com/highlight/detail?id=1170196264","media":"Motley Fool","summary":"Stocks fell sharply overall, but one group of disruptors is dealing with specific concerns.\n\nKey Poi","content":"<blockquote>\n <b>Stocks fell sharply overall, but one group of disruptors is dealing with specific concerns.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Markets fell sharply on Tuesday.</li>\n <li>Buy now, pay later stocks Affirm Holdings and Square were down on news that Mastercard is entering the space.</li>\n <li>Other big companies could make similar moves against smaller rivals.</li>\n</ul>\n<p>Wall Street suffered its toughest day in a long time on Tuesday, as major market indexes moved sharply lower. Losses for the&nbsp;<b>Dow Jones Industrial Average</b>(DJINDICES:^DJI)and&nbsp;<b>S&amp;P 500</b>(SNPINDEX:^GSPC)&nbsp;amounted to roughly 1.5% to 2%, but the&nbsp;<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)&nbsp;saw even deeper drops that reflected investors' skittishness about some of the high-flying stocks that have led the market's rally over the past 18 months.</p>\n<p>Many disruptive small-cap companies in high-growth areas like technology, biotech, and&nbsp;fintech&nbsp;have posted huge gains over the past year and a half, led higher by the prospects for their businesses to usurp existing players in their respective industries. Yet it's too much to believe that industry leaders won't fight back.</p>\n<p>That's a lesson that investors in stocks in the popular&nbsp;buy now, pay later(BNPL) niche learned on Tuesday, and those who've invested in other stocks taking advantage of disruptive innovation need to reassess whether the companies they're seeking to displace won't have similar opportunities to try to counter their strategic moves.</p>\n<p>A big move lower for buy now, pay later</p>\n<p>Stocks that have benefited the most from the rise of interest in BNPL services took some big hits on Tuesday.&nbsp;<b>Affirm Holdings</b>(NASDAQ:AFRM)was lower by 11% by the close. Shares of Australian BNPL specialist&nbsp;<b>Afterpay</b>(OTC:AFTP.Y)fell almost 6%, moving almost in lockstep with U.S. rising financial star&nbsp;<b>Square</b>(NYSE:SQ), which is set tobuy Afterpay in an all-stock acquisitioninitially valued at $29 billion.</p>\n<p>The news that hit these stocks came from credit card industry giant&nbsp;<b>Mastercard</b>(NYSE:MA). The company announced its new Mastercard Installment program, which will be available in the U.K., the U.S., and Australia. The BNPL program will have many of the same features consumers have come to expect from Afterpay and Affirm, including interest-free installment payments. Yet Mastercard argues that its program's integration into its existing electronic payments network is a competitive advantage that will make BNPL eventually available across the card giant's entire global network.</p>\n<p>Mastercard intends to count on its vast network of lenders and merchants to help make its program a success. To the extent that consumers agree, the company will be able to make transaction histories known to lenders as part of their decision-making process for underwriting installment arrangements. This could lead to more-extensive credit availability for shoppers. Moreover, Mastercard believes that BNPL could help merchants by boosting sales and reducing abandoned online carts.</p>\n<p>At the same time, Mastercard touted its zero-liability fraud protection as a feature. That's something its rivals aren't typically offering.</p>\n<p>Interestingly, the company has put together a large set of partners for its rollout. Some are mainstays in the financial community, including&nbsp;<b>Barclays</b>,&nbsp;<b>Fifth Third Bancorp</b>, and&nbsp;<b>Synchrony Financial</b>. Others are newer, including neobank&nbsp;<b>SoFi Technologies</b>and card-issuing platform provider&nbsp;<b>Marqeta</b>.</p>\n<p>A broadside for disruptors</p>\n<p>Mastercard's entry into BNPL is just one example of the many ways that current leaders in many industries will fight back against high-growth small caps trying to take away their business. The move won't be fatal to Affirm or Square, but it serves as a valuable reminder that disruptors won't have the field to themselves -- and need to be prepared to fight for supremacy in the areas in which they've become pioneers.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Every High-Growth Investor Must Keep This Huge Threat in Mind</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvery High-Growth Investor Must Keep This Huge Threat in Mind\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-29 07:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/every-high-growth-investor-keep-huge-threat-mind/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks fell sharply overall, but one group of disruptors is dealing with specific concerns.\n\nKey Points\n\nMarkets fell sharply on Tuesday.\nBuy now, pay later stocks Affirm Holdings and Square were down...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/every-high-growth-investor-keep-huge-threat-mind/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.fool.com/investing/2021/09/28/every-high-growth-investor-keep-huge-threat-mind/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170196264","content_text":"Stocks fell sharply overall, but one group of disruptors is dealing with specific concerns.\n\nKey Points\n\nMarkets fell sharply on Tuesday.\nBuy now, pay later stocks Affirm Holdings and Square were down on news that Mastercard is entering the space.\nOther big companies could make similar moves against smaller rivals.\n\nWall Street suffered its toughest day in a long time on Tuesday, as major market indexes moved sharply lower. Losses for the Dow Jones Industrial Average(DJINDICES:^DJI)and S&P 500(SNPINDEX:^GSPC) amounted to roughly 1.5% to 2%, but the Nasdaq Composite(NASDAQINDEX:^IXIC) saw even deeper drops that reflected investors' skittishness about some of the high-flying stocks that have led the market's rally over the past 18 months.\nMany disruptive small-cap companies in high-growth areas like technology, biotech, and fintech have posted huge gains over the past year and a half, led higher by the prospects for their businesses to usurp existing players in their respective industries. Yet it's too much to believe that industry leaders won't fight back.\nThat's a lesson that investors in stocks in the popular buy now, pay later(BNPL) niche learned on Tuesday, and those who've invested in other stocks taking advantage of disruptive innovation need to reassess whether the companies they're seeking to displace won't have similar opportunities to try to counter their strategic moves.\nA big move lower for buy now, pay later\nStocks that have benefited the most from the rise of interest in BNPL services took some big hits on Tuesday. Affirm Holdings(NASDAQ:AFRM)was lower by 11% by the close. Shares of Australian BNPL specialist Afterpay(OTC:AFTP.Y)fell almost 6%, moving almost in lockstep with U.S. rising financial star Square(NYSE:SQ), which is set tobuy Afterpay in an all-stock acquisitioninitially valued at $29 billion.\nThe news that hit these stocks came from credit card industry giant Mastercard(NYSE:MA). The company announced its new Mastercard Installment program, which will be available in the U.K., the U.S., and Australia. The BNPL program will have many of the same features consumers have come to expect from Afterpay and Affirm, including interest-free installment payments. Yet Mastercard argues that its program's integration into its existing electronic payments network is a competitive advantage that will make BNPL eventually available across the card giant's entire global network.\nMastercard intends to count on its vast network of lenders and merchants to help make its program a success. To the extent that consumers agree, the company will be able to make transaction histories known to lenders as part of their decision-making process for underwriting installment arrangements. This could lead to more-extensive credit availability for shoppers. Moreover, Mastercard believes that BNPL could help merchants by boosting sales and reducing abandoned online carts.\nAt the same time, Mastercard touted its zero-liability fraud protection as a feature. That's something its rivals aren't typically offering.\nInterestingly, the company has put together a large set of partners for its rollout. Some are mainstays in the financial community, including Barclays, Fifth Third Bancorp, and Synchrony Financial. Others are newer, including neobank SoFi Technologiesand card-issuing platform provider Marqeta.\nA broadside for disruptors\nMastercard's entry into BNPL is just one example of the many ways that current leaders in many industries will fight back against high-growth small caps trying to take away their business. The move won't be fatal to Affirm or Square, but it serves as a valuable reminder that disruptors won't have the field to themselves -- and need to be prepared to fight for supremacy in the areas in which they've become pioneers.","news_type":1},"isVote":1,"tweetType":1,"viewCount":12,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":809309798,"gmtCreate":1627346391414,"gmtModify":1633765927018,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"LMC: losses? Sorry, it is unclassified[龇牙]&nbsp;[龇牙]&nbsp;","listText":"LMC: losses? Sorry, it is unclassified[龇牙]&nbsp;[龇牙]&nbsp;","text":"LMC: losses? Sorry, it is unclassified[龇牙] [龇牙]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/809309798","repostId":"2154964378","repostType":4,"isVote":1,"tweetType":1,"viewCount":125,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":822697247,"gmtCreate":1634123430793,"gmtModify":1634123431098,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Strong boost for stock market today!","listText":"Strong boost for stock market today!","text":"Strong boost for stock market today!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/822697247","repostId":"2175152592","repostType":4,"repost":{"id":"2175152592","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1634122062,"share":"https://www.laohu8.com/m/news/2175152592?lang=&edition=full","pubTime":"2021-10-13 18:47","market":"us","language":"en","title":"JPMorgan Chase Q3 EPS $3.74 Beats $3.00 Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2175152592","media":"Benzinga","summary":"-Dow Jones","content":"<p>JPMorgan Chase &amp; Co&nbsp;reported a jump in third-quarter earnings on Wednesday, as the largest U.S. bank's Wall Street arm capitalized on a global dealmaking boom.</p>\n<p>JPMorgan's net income rose to $11.7 billion, or $3.74 per share, in the quarter ended Sept. 30, compared with $9.4 billion, or $2.92 per share, a year earlier.</p>\n<p>Analysts on average had expected earnings of $3.00 per share, according to Refinitiv.</p>\n<p><img src=\"https://static.tigerbbs.com/d9a19448ee10d9f8c7752c706a1008e4\" tg-width=\"1029\" tg-height=\"381\" referrerpolicy=\"no-referrer\"></p>\n<p>The&nbsp;shares&nbsp;rose&nbsp;0.5%&nbsp;in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/b93eba6cab488f2d83cd244be3c9369b\" tg-width=\"850\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p><b>THIRD-QUARTER 2021 RESULTS</b></p>\n<ul>\n <li>Reported revenue of $29.6 billion; managed revenue of $30.4 billion</li>\n</ul>\n<ul>\n <li>Credit costs net benefit of $1.5 billion included $2.1 billion of net reserve release and $524 million of net charge-offs</li>\n</ul>\n<ul>\n <li>Average loans up 5%; average deposits up 19%$1.6 trillion of liquidity sources, including HQLA and unencumbered marketable securities</li>\n</ul>\n<ul>\n <li>Average deposits up 20%; client investment assets up 29%</li>\n</ul>\n<ul>\n <li>Average loans down 2% YoY and up 1% QoQ; Card net charge-off rate of 1.39%</li>\n</ul>\n<ul>\n <li>Debit and credit card sales volume up 26%</li>\n</ul>\n<ul>\n <li>Active mobile customers up 10%</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JPMorgan Chase Q3 EPS $3.74 Beats $3.00 Estimate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJPMorgan Chase Q3 EPS $3.74 Beats $3.00 Estimate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-10-13 18:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>JPMorgan Chase &amp; Co&nbsp;reported a jump in third-quarter earnings on Wednesday, as the largest U.S. bank's Wall Street arm capitalized on a global dealmaking boom.</p>\n<p>JPMorgan's net income rose to $11.7 billion, or $3.74 per share, in the quarter ended Sept. 30, compared with $9.4 billion, or $2.92 per share, a year earlier.</p>\n<p>Analysts on average had expected earnings of $3.00 per share, according to Refinitiv.</p>\n<p><img src=\"https://static.tigerbbs.com/d9a19448ee10d9f8c7752c706a1008e4\" tg-width=\"1029\" tg-height=\"381\" referrerpolicy=\"no-referrer\"></p>\n<p>The&nbsp;shares&nbsp;rose&nbsp;0.5%&nbsp;in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/b93eba6cab488f2d83cd244be3c9369b\" tg-width=\"850\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p><b>THIRD-QUARTER 2021 RESULTS</b></p>\n<ul>\n <li>Reported revenue of $29.6 billion; managed revenue of $30.4 billion</li>\n</ul>\n<ul>\n <li>Credit costs net benefit of $1.5 billion included $2.1 billion of net reserve release and $524 million of net charge-offs</li>\n</ul>\n<ul>\n <li>Average loans up 5%; average deposits up 19%$1.6 trillion of liquidity sources, including HQLA and unencumbered marketable securities</li>\n</ul>\n<ul>\n <li>Average deposits up 20%; client investment assets up 29%</li>\n</ul>\n<ul>\n <li>Average loans down 2% YoY and up 1% QoQ; Card net charge-off rate of 1.39%</li>\n</ul>\n<ul>\n <li>Debit and credit card sales volume up 26%</li>\n</ul>\n<ul>\n <li>Active mobile customers up 10%</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JPM":"摩根大通"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175152592","content_text":"JPMorgan Chase & Co reported a jump in third-quarter earnings on Wednesday, as the largest U.S. bank's Wall Street arm capitalized on a global dealmaking boom.\nJPMorgan's net income rose to $11.7 billion, or $3.74 per share, in the quarter ended Sept. 30, compared with $9.4 billion, or $2.92 per share, a year earlier.\nAnalysts on average had expected earnings of $3.00 per share, according to Refinitiv.\n\nThe shares rose 0.5% in premarket trading.\n\nTHIRD-QUARTER 2021 RESULTS\n\nReported revenue of $29.6 billion; managed revenue of $30.4 billion\n\n\nCredit costs net benefit of $1.5 billion included $2.1 billion of net reserve release and $524 million of net charge-offs\n\n\nAverage loans up 5%; average deposits up 19%$1.6 trillion of liquidity sources, including HQLA and unencumbered marketable securities\n\n\nAverage deposits up 20%; client investment assets up 29%\n\n\nAverage loans down 2% YoY and up 1% QoQ; Card net charge-off rate of 1.39%\n\n\nDebit and credit card sales volume up 26%\n\n\nActive mobile customers up 10%","news_type":1},"isVote":1,"tweetType":1,"viewCount":64,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":101145485,"gmtCreate":1619868424847,"gmtModify":1634209390916,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Biotech startup companies are always high risk high reward, avoid them unless you are very positive in their development and breakthrough..[正经]&nbsp;[正经]&nbsp;","listText":"Biotech startup companies are always high risk high reward, avoid them unless you are very positive in their development and breakthrough..[正经]&nbsp;[正经]&nbsp;","text":"Biotech startup companies are always high risk high reward, avoid them unless you are very positive in their development and breakthrough..[正经] [正经]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/101145485","repostId":"1165708828","repostType":4,"isVote":1,"tweetType":1,"viewCount":50,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605519516,"gmtCreate":1639189464463,"gmtModify":1639189872017,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Wait till next week after Fed meeting then only decide what is the next step","listText":"Wait till next week after Fed meeting then only decide what is the next step","text":"Wait till next week after Fed meeting then only decide what is the next step","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605519516","repostId":"1133027099","repostType":4,"repost":{"id":"1133027099","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639152670,"share":"https://www.laohu8.com/m/news/1133027099?lang=&edition=full","pubTime":"2021-12-11 00:11","market":"us","language":"en","title":"Sea Ltd stock dropped more than 5% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133027099","media":"Tiger Newspress","summary":"Sea Ltd stock dropped more than 5% in morning trading.","content":"<p>Sea Ltd stock dropped more than 5% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f6295277426435ac2c7135ba73dfbdef\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sea Ltd stock dropped more than 5% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSea Ltd stock dropped more than 5% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-11 00:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sea Ltd stock dropped more than 5% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f6295277426435ac2c7135ba73dfbdef\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133027099","content_text":"Sea Ltd stock dropped more than 5% in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":627,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842201678,"gmtCreate":1636176579496,"gmtModify":1636177013689,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"At least one obstacle is cleared.","listText":"At least one obstacle is cleared.","text":"At least one obstacle is cleared.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/842201678","repostId":"2181742831","repostType":2,"repost":{"id":"2181742831","pubTimestamp":1636169123,"share":"https://www.laohu8.com/m/news/2181742831?lang=&edition=full","pubTime":"2021-11-06 11:25","market":"us","language":"en","title":"US Democrats pass $1.35 trillion infrastructure Bill, ending daylong stand-off","url":"https://stock-news.laohu8.com/highlight/detail?id=2181742831","media":"The Straits Times","summary":"WASHINGTON (REUTERS) - After a daylong stand-off, Democrats set aside divisions between progressives","content":"<div>\n<p>WASHINGTON (REUTERS) - After a daylong stand-off, Democrats set aside divisions between progressives and centrists to pass a US$1 trillion (S$1.35 trillion) package of highway, broadband and other ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/us-democrats-pass-135-trillion-infrastructure-bill-ending-daylong-stand-off\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US Democrats pass $1.35 trillion infrastructure Bill, ending daylong stand-off</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS Democrats pass $1.35 trillion infrastructure Bill, ending daylong stand-off\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-06 11:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/us-democrats-pass-135-trillion-infrastructure-bill-ending-daylong-stand-off><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (REUTERS) - After a daylong stand-off, Democrats set aside divisions between progressives and centrists to pass a US$1 trillion (S$1.35 trillion) package of highway, broadband and other ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/us-democrats-pass-135-trillion-infrastructure-bill-ending-daylong-stand-off\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"http://www.straitstimes.com/world/united-states/us-democrats-pass-135-trillion-infrastructure-bill-ending-daylong-stand-off","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2181742831","content_text":"WASHINGTON (REUTERS) - After a daylong stand-off, Democrats set aside divisions between progressives and centrists to pass a US$1 trillion (S$1.35 trillion) package of highway, broadband and other infrastructure improvement, sending it on to US President Joe Biden to sign into law.\nThe 228-to-206 vote is a substantial triumph for Biden’s Democrats, who have bickered for months over the ambitious spending Bills that make up the bulk of his domestic agenda.\nBiden’s administration will now oversee the biggest upgrade of America’s roads, railways and other transportation infrastructure in a generation, which he has promised will create jobs and boost US  competitiveness.\nDemocrats still have much work to do on the second pillar of Biden’s domestic programme: a sweeping expansion of the social safety net and programs to fight climate change.\nAt a price tag of US$1.75 trillion, that package would be the biggest expansion of the US safety net since the 1960s, but the party has struggled to unite behind it.\nDemocratic leaders had hoped to pass both Bills out of the House on Friday, but postponed action after centrists demanded a nonpartisan accounting of its costs – a process that could take weeks.\nAfter hours of closed-door meetings, a group of centrists promised to vote for the Bill by Nov 20 – as long as the nonpartisan Congressional Budget Office found that its costs lined up with White House estimates.\nThe House planned a procedural vote on that package later on Friday.\n\"Welcome to my world. This is the Democratic Party,\" House Speaker Nancy Pelosi told reporters earlier in the day. \"We are not a lockstep party.\"\nThe stand-off came just days after Democrats suffered losses in closely watched state elections, raising concerns that they may lose control of Congress next year.\nBiden called lawmakers to urge them to pass the transportation package, which has already won approval in the Senate.\nThe infrastructure Bill passed with the support of 13 Republicans, fulfilling Biden’s promise of passing some bipartisan legislation.\nThe phrase \"infrastructure week\" had become a Washington punchline during his predecessor Donald Trump’s four years in the White House, when plans to focus on those investments were repeatedly derailed by scandals.\nThe party is eager to show it can move forward on the president's agenda and fend off Republicans in the 2022 midterm elections, when control of the House and Senate will be on the line.\nCongress also faces looming Dec 3 deadlines to avert a politically embarrassing government shutdown and an economically catastrophic default on the federal government's debt.\nWith razor-thin majorities in Congress and a united Republican opposition, Democrats need unity to pass legislation.\nThe infrastructure Bill, which passed the Senate in August with 19 Republican votes, would fund a massive upgrade of America's roads, bridges, airports, seaports and rail systems, while also expanding broadband Internet service.\nThe \"Build Back Better\" package includes provisions on child care and preschool, eldercare, healthcare, prescription drug pricing and immigration.\nIt would bolster the credibility of Biden’s pledge to halve US greenhouse gas emissions from 2005 levels by 2030 during the UN climate conference taking place in Glasgow, Scotland.\nRepublicans uniformly oppose that legislation, casting it as a dramatic expansion of government that would hurt businesses.\nPelosi and other top Democrats have said that fails to account for increased tax enforcement and savings from lower prescription drug prices.","news_type":1},"isVote":1,"tweetType":1,"viewCount":4,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842699922,"gmtCreate":1636167039603,"gmtModify":1636167040631,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"We finally can see the end of this pandemic soon","listText":"We finally can see the end of this pandemic soon","text":"We finally can see the end of this pandemic soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842699922","repostId":"1152406340","repostType":2,"repost":{"id":"1152406340","pubTimestamp":1636157546,"share":"https://www.laohu8.com/m/news/1152406340?lang=&edition=full","pubTime":"2021-11-06 08:12","market":"us","language":"en","title":"Will Pfizer Outgun Merck With Oral COVID-19 Pill?","url":"https://stock-news.laohu8.com/highlight/detail?id=1152406340","media":"Benzinga","summary":"Merck, Inc. is locking horns with peer Pfizer, Inc. in what could be termed as the battle supremacy ","content":"<p><b>Merck, Inc.</b>&nbsp;is locking horns with peer&nbsp;<b>Pfizer, Inc.</b>&nbsp;in what could be termed as the battle supremacy in the COVID-19 treatment market.</p>\n<p>The stakes are high, with&nbsp;an effective treatment for the disease potentially entering the arena in addition to the vaccines that are already on the market.</p>\n<p><b>Pfizer Dips Into COVID-19 Treatment Arena:</b>After acing the&nbsp;COVID-19 vaccine race&nbsp;along with its German partner&nbsp;<b>BioNTech SE</b>, Pfizer is wanting to leave no stone unturned in capitalizing on the COVID opportunity.</p>\n<p>The company announced Friday an interim analysis of data from the Phase 2/3 study of its oral COVID-19 antiviral candidate Paxlovid, showing an 89% reduction in the risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset.</p>\n<p>The positive data triggered strong buying in Pfizer shares and a sell-off in Merck shares.</p>\n<p>Merck had its share of upside in early October when it reported positive Phase 3 data for an&nbsp;oral COVID-19 pill,&nbsp;molnupiravir, that it's co-developing the treatment with Ridgeback Biotherapeutics. The Merck news triggered an across-the-board sell-off in vaccine stocks at that time.</p>\n<p>These two companies with deep pockets and marketing expertise are vying for a piece of the COVID-19 treatment market, making the competitive landscape all the more interesting.</p>\n<p><b>Pfizer Vs. Merck Data Comparison:</b>As opposed the 89% reduction in risk of hospitalization or death reported by Pfizer for Paxlovid, an interim analysis of Merck's Phase 3 data released on Oct. 1 showed molnupiravir reducing the risk of hospitalization or death by approximately 50%.</p>\n<p>Only about 0.8% of patients who received Paxlovid were hospitalized through day 28 compared to 7% of patients who received placebo and were hospitalized or died.</p>\n<p>Similar reductions in COVID-19-related hospitalization or death were observed in patients treated within five days of symptom onset.</p>\n<p>Merck reported that 7.3% of patients who received molnupiravir were either hospitalized or died through day 29 compared with 14.1% of placebo-treated patients.</p>\n<p>Through day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo. With Merck, through day 29, no deaths were reported in patients who received molnupiravir, as compared to eight&nbsp;deaths in patients who received placebo.</p>\n<p>Not only is Pfizer's drug safe, but the level of efficacy is so high that it will very meaningfully shake up the COVID landscape looking to next year— including the outlook for boosters, BofA Securities analyst Geoff Meacham said in a note.</p>\n<p>\"Between&nbsp;<b>Roche Holding AG's</b>&nbsp;recent failure and Merck's decent efficacy, Pfizer's drug will be the clear best-in-class oral, and well positioned to capitalize on the longer term C-19 treatment market that could be in the mid-to-high billions next year,\" Meacham said.</p>\n<p><b>Authorization Before Year-End?</b>At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration, Pfizer will cease further enrollment into the study due to the overwhelming efficacy demonstrated in these results, the company said.</p>\n<p>It plans to submit the data as part of its ongoing rolling submission to the authorization as soon as possible.</p>\n<p>BofA expects the application to be soon submitted to the FDA, with&nbsp;an authorization likely&nbsp;by the end of the year.</p>\n<p>Meanwhile, Merck announced Thursday it has received the first authorization for molnupiravir in the U.K., with the drug to be marketed under the brand name Lagevrio.</p>\n<p>Its application with the FDA is under review. The European Medicines Agency has recently initiated a rolling review of its Marketing Authorization Application. Merck also said it is actively working to submit applications to other regulatory agencies around the world.</p>\n<p>The commercial outlook could dramatically shift in favor of Pfizer's pill given how much more impressive the data is, BofA said. Merck's revenue guidance of $5 billion to $7 billion through 2022 provided on its third-quarter call last week could be reduced meaningfully, the firm added.</p>\n<p>Meanwhile,&nbsp;<b>Gilead, Inc.'s</b>&nbsp;antiviral remdesivir could remain an option for hospitalized patients, but overall its use is likely to further diminish, in BofA's view.</p>\n<p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Pfizer Outgun Merck With Oral COVID-19 Pill?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Pfizer Outgun Merck With Oral COVID-19 Pill?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-06 08:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/23925379/will-pfizer-outgun-merck-with-oral-covid-19-pill><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Merck, Inc. is locking horns with peer Pfizer, Inc. in what could be termed as the battle supremacy in the COVID-19 treatment market.\nThe stakes are high, with an effective treatment for the disease ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/23925379/will-pfizer-outgun-merck-with-oral-covid-19-pill\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRK":"默沙东"},"source_url":"https://www.benzinga.com/general/biotech/21/11/23925379/will-pfizer-outgun-merck-with-oral-covid-19-pill","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152406340","content_text":"Merck, Inc. is locking horns with peer Pfizer, Inc. in what could be termed as the battle supremacy in the COVID-19 treatment market.\nThe stakes are high, with an effective treatment for the disease potentially entering the arena in addition to the vaccines that are already on the market.\nPfizer Dips Into COVID-19 Treatment Arena:After acing the COVID-19 vaccine race along with its German partner BioNTech SE, Pfizer is wanting to leave no stone unturned in capitalizing on the COVID opportunity.\nThe company announced Friday an interim analysis of data from the Phase 2/3 study of its oral COVID-19 antiviral candidate Paxlovid, showing an 89% reduction in the risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset.\nThe positive data triggered strong buying in Pfizer shares and a sell-off in Merck shares.\nMerck had its share of upside in early October when it reported positive Phase 3 data for an oral COVID-19 pill, molnupiravir, that it's co-developing the treatment with Ridgeback Biotherapeutics. The Merck news triggered an across-the-board sell-off in vaccine stocks at that time.\nThese two companies with deep pockets and marketing expertise are vying for a piece of the COVID-19 treatment market, making the competitive landscape all the more interesting.\nPfizer Vs. Merck Data Comparison:As opposed the 89% reduction in risk of hospitalization or death reported by Pfizer for Paxlovid, an interim analysis of Merck's Phase 3 data released on Oct. 1 showed molnupiravir reducing the risk of hospitalization or death by approximately 50%.\nOnly about 0.8% of patients who received Paxlovid were hospitalized through day 28 compared to 7% of patients who received placebo and were hospitalized or died.\nSimilar reductions in COVID-19-related hospitalization or death were observed in patients treated within five days of symptom onset.\nMerck reported that 7.3% of patients who received molnupiravir were either hospitalized or died through day 29 compared with 14.1% of placebo-treated patients.\nThrough day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo. With Merck, through day 29, no deaths were reported in patients who received molnupiravir, as compared to eight deaths in patients who received placebo.\nNot only is Pfizer's drug safe, but the level of efficacy is so high that it will very meaningfully shake up the COVID landscape looking to next year— including the outlook for boosters, BofA Securities analyst Geoff Meacham said in a note.\n\"Between Roche Holding AG's recent failure and Merck's decent efficacy, Pfizer's drug will be the clear best-in-class oral, and well positioned to capitalize on the longer term C-19 treatment market that could be in the mid-to-high billions next year,\" Meacham said.\nAuthorization Before Year-End?At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration, Pfizer will cease further enrollment into the study due to the overwhelming efficacy demonstrated in these results, the company said.\nIt plans to submit the data as part of its ongoing rolling submission to the authorization as soon as possible.\nBofA expects the application to be soon submitted to the FDA, with an authorization likely by the end of the year.\nMeanwhile, Merck announced Thursday it has received the first authorization for molnupiravir in the U.K., with the drug to be marketed under the brand name Lagevrio.\nIts application with the FDA is under review. The European Medicines Agency has recently initiated a rolling review of its Marketing Authorization Application. Merck also said it is actively working to submit applications to other regulatory agencies around the world.\nThe commercial outlook could dramatically shift in favor of Pfizer's pill given how much more impressive the data is, BofA said. Merck's revenue guidance of $5 billion to $7 billion through 2022 provided on its third-quarter call last week could be reduced meaningfully, the firm added.\nMeanwhile, Gilead, Inc.'s antiviral remdesivir could remain an option for hospitalized patients, but overall its use is likely to further diminish, in BofA's view.","news_type":1},"isVote":1,"tweetType":1,"viewCount":26,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854881461,"gmtCreate":1635432777909,"gmtModify":1635432779547,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Finally see some light at the end of tunnel","listText":"Finally see some light at the end of tunnel","text":"Finally see some light at the end of tunnel","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/854881461","repostId":"2178267992","repostType":4,"repost":{"id":"2178267992","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1635432578,"share":"https://www.laohu8.com/m/news/2178267992?lang=&edition=full","pubTime":"2021-10-28 22:49","market":"us","language":"en","title":"Teladoc Health Stock Gains After Q3 Results, Clocks 81% Top-Line Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2178267992","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>Teladoc Health Inc&nbsp;</b>(NYSE:TDOC)&nbsp;posted a narrower than expected Q3 EPS loss of $(0.53)&nbsp;versus consensus of $(0.65), though loss widened when compared to $(0.43) reported a year ago.</li>\n <li>Q3 net loss included a stock-based compensation expense of $71.7 million, reflecting Livongo stock awards.</li>\n <li>Teladoc managed to grow its top line by 81% to $521.66 million, beating the consensus of $516.63 million.</li>\n <li>During the quarter, the company saw visits jump to 3.9 million, +37% Y/Y,</li>\n <li>Paid memberships in the U.S. were 52.5 million, up 2% Y/Y.</li>\n <li>The average revenue per member per month was $2.57, up from $1.18 last year and $2.47 in 2Q21, the company mentioned in the Q3 earnings conference call.</li>\n <li>Adjusted EBITDA was $67.4 million compared to $39.5 million a year ago.</li>\n <li><b>FY2021 guidance:&nbsp;</b>Teladoc forecasts sales of $2.015 billion - $2.025 billion, with EPS loss of $(3.40) - $(3.20), compared to&nbsp;earlier guidance&nbsp;of $2 billion - $2.025 billion and $(3.60) to $(3.35), respectively.</li>\n <li>It anticipates 14.5 million - 14.7 million total visits, with U.S. paid memberships of 52.5 million - 53.5 million.</li>\n <li>For Q4, Teladoc sees sales of $536 million - $546 million (consensus $539.74 million), and EPS loss of $(0.73) - $(0.53). It anticipates 3.9 million - 4.1 million total visits for Q4.</li>\n <li><b>Price Action:</b>&nbsp;TDOC shares are up 5.68% at $146.50 on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teladoc Health Stock Gains After Q3 Results, Clocks 81% Top-Line Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeladoc Health Stock Gains After Q3 Results, Clocks 81% Top-Line Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-10-28 22:49</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>Teladoc Health Inc&nbsp;</b>(NYSE:TDOC)&nbsp;posted a narrower than expected Q3 EPS loss of $(0.53)&nbsp;versus consensus of $(0.65), though loss widened when compared to $(0.43) reported a year ago.</li>\n <li>Q3 net loss included a stock-based compensation expense of $71.7 million, reflecting Livongo stock awards.</li>\n <li>Teladoc managed to grow its top line by 81% to $521.66 million, beating the consensus of $516.63 million.</li>\n <li>During the quarter, the company saw visits jump to 3.9 million, +37% Y/Y,</li>\n <li>Paid memberships in the U.S. were 52.5 million, up 2% Y/Y.</li>\n <li>The average revenue per member per month was $2.57, up from $1.18 last year and $2.47 in 2Q21, the company mentioned in the Q3 earnings conference call.</li>\n <li>Adjusted EBITDA was $67.4 million compared to $39.5 million a year ago.</li>\n <li><b>FY2021 guidance:&nbsp;</b>Teladoc forecasts sales of $2.015 billion - $2.025 billion, with EPS loss of $(3.40) - $(3.20), compared to&nbsp;earlier guidance&nbsp;of $2 billion - $2.025 billion and $(3.60) to $(3.35), respectively.</li>\n <li>It anticipates 14.5 million - 14.7 million total visits, with U.S. paid memberships of 52.5 million - 53.5 million.</li>\n <li>For Q4, Teladoc sees sales of $536 million - $546 million (consensus $539.74 million), and EPS loss of $(0.73) - $(0.53). It anticipates 3.9 million - 4.1 million total visits for Q4.</li>\n <li><b>Price Action:</b>&nbsp;TDOC shares are up 5.68% at $146.50 on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2178267992","content_text":"Teladoc Health Inc (NYSE:TDOC) posted a narrower than expected Q3 EPS loss of $(0.53) versus consensus of $(0.65), though loss widened when compared to $(0.43) reported a year ago.\nQ3 net loss included a stock-based compensation expense of $71.7 million, reflecting Livongo stock awards.\nTeladoc managed to grow its top line by 81% to $521.66 million, beating the consensus of $516.63 million.\nDuring the quarter, the company saw visits jump to 3.9 million, +37% Y/Y,\nPaid memberships in the U.S. were 52.5 million, up 2% Y/Y.\nThe average revenue per member per month was $2.57, up from $1.18 last year and $2.47 in 2Q21, the company mentioned in the Q3 earnings conference call.\nAdjusted EBITDA was $67.4 million compared to $39.5 million a year ago.\nFY2021 guidance: Teladoc forecasts sales of $2.015 billion - $2.025 billion, with EPS loss of $(3.40) - $(3.20), compared to earlier guidance of $2 billion - $2.025 billion and $(3.60) to $(3.35), respectively.\nIt anticipates 14.5 million - 14.7 million total visits, with U.S. paid memberships of 52.5 million - 53.5 million.\nFor Q4, Teladoc sees sales of $536 million - $546 million (consensus $539.74 million), and EPS loss of $(0.73) - $(0.53). It anticipates 3.9 million - 4.1 million total visits for Q4.\nPrice Action: TDOC shares are up 5.68% at $146.50 on the last check Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":54,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":868670586,"gmtCreate":1632645314245,"gmtModify":1632646525023,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Time to sell and get your profit...","listText":"Time to sell and get your profit...","text":"Time to sell and get your profit...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/868670586","repostId":"1107241271","repostType":4,"repost":{"id":"1107241271","pubTimestamp":1632642043,"share":"https://www.laohu8.com/m/news/1107241271?lang=&edition=full","pubTime":"2021-09-26 15:40","market":"hk","language":"en","title":"Why Bitcoin, Ethereum And Dogecoin Could Be In For A Bumpy Road Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=1107241271","media":"Benzinga","summary":"Thousands of traders just like you are earning second income stream trading options! Click Here See ","content":"<p>Thousands of traders just like you are earning second income stream trading options! Click Here See How!</p>\n<p>Bitcoin (CRYPTO: BTC), Dogecoin (CRYPTO: DOGE) and Ethereum (CRYPTO: ETH) have developed inside bar patterns on the daily chart. An inside bar pattern indicates a period of consolidation and is usually followed by a continuation move in the direction of the current trend.</p>\n<p>An inside bar pattern has more validity on larger time frames (four-hour chart or larger). The pattern has a minimum of two candlesticks and consists of a mother bar (the first candlestick in the pattern) followed by one or more subsequent candles. The subsequent candle(s) must be completely inside the range of the mother bar and each is called an \"inside bar.\"</p>\n<p>A double, or triple inside bar can be more powerful than a single inside bar. After the break of an inside bar pattern, traders want to watch for high volume as confirmation the pattern was recognized.</p>\n<p>Bullish traders will want to search for inside bar patterns on stocks that are in an uptrend. Some traders may take a position during the inside bar prior to the break while other aggressive traders will take a position after the break of the pattern.</p>\n<p>For bearish traders, finding an inside bar pattern on a stock that's in a downtrend will be key. Like bullish traders, bears have two options of where to take a position to play the break of the pattern. For bearish traders, the pattern is invalidated if the stock rises above the highest range of the mother candle.</p>\n<p>The Bitcoin Chart: Bitcoin was printing an inside bar on the daily chart just above a support level at $42,223. The crypto is trading in a short uptrend within a larger downtrend. Bitcoin will have to make a higher high above the $55,200 level for confirmation the downtrend is over.</p>\n<p><img src=\"https://static.tigerbbs.com/b6c00a691a64e89a6b81a0ec2e682087\" tg-width=\"1366\" tg-height=\"768\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"><b>The Dogecoin Chart:</b>Dogecoin is trading in a steep downtrend but holding above a key support level of $0.197. The crypto's inside bar on Saturday demonstrates consolidation. If Dogecoin loses support at its key level it could fall toward the 16-cent mark.</p>\n<p><img src=\"https://static.tigerbbs.com/fc70a3ccbf56e44573ebb113831867b3\" tg-width=\"1366\" tg-height=\"768\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"><b>The Ethereum Chart:</b>Like Bitcoin, Ethereum may be working to reverse course into an uptrend but will need to shoot up above Thursday's high of $3182 for confirmation. Otherwise, the crypto could continue lower in its larger downtrend following Saturday's inside bar.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bitcoin, Ethereum And Dogecoin Could Be In For A Bumpy Road Ahead</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bitcoin, Ethereum And Dogecoin Could Be In For A Bumpy Road Ahead\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-26 15:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/cryptocurrency/21/09/23101760/why-bitcoin-ethereum-and-dogecoin-could-be-in-for-a-bumpy-road-ahead><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Thousands of traders just like you are earning second income stream trading options! Click Here See How!\nBitcoin (CRYPTO: BTC), Dogecoin (CRYPTO: DOGE) and Ethereum (CRYPTO: ETH) have developed inside...</p>\n\n<a href=\"https://www.benzinga.com/markets/cryptocurrency/21/09/23101760/why-bitcoin-ethereum-and-dogecoin-could-be-in-for-a-bumpy-road-ahead\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/markets/cryptocurrency/21/09/23101760/why-bitcoin-ethereum-and-dogecoin-could-be-in-for-a-bumpy-road-ahead","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107241271","content_text":"Thousands of traders just like you are earning second income stream trading options! Click Here See How!\nBitcoin (CRYPTO: BTC), Dogecoin (CRYPTO: DOGE) and Ethereum (CRYPTO: ETH) have developed inside bar patterns on the daily chart. An inside bar pattern indicates a period of consolidation and is usually followed by a continuation move in the direction of the current trend.\nAn inside bar pattern has more validity on larger time frames (four-hour chart or larger). The pattern has a minimum of two candlesticks and consists of a mother bar (the first candlestick in the pattern) followed by one or more subsequent candles. The subsequent candle(s) must be completely inside the range of the mother bar and each is called an \"inside bar.\"\nA double, or triple inside bar can be more powerful than a single inside bar. After the break of an inside bar pattern, traders want to watch for high volume as confirmation the pattern was recognized.\nBullish traders will want to search for inside bar patterns on stocks that are in an uptrend. Some traders may take a position during the inside bar prior to the break while other aggressive traders will take a position after the break of the pattern.\nFor bearish traders, finding an inside bar pattern on a stock that's in a downtrend will be key. Like bullish traders, bears have two options of where to take a position to play the break of the pattern. For bearish traders, the pattern is invalidated if the stock rises above the highest range of the mother candle.\nThe Bitcoin Chart: Bitcoin was printing an inside bar on the daily chart just above a support level at $42,223. The crypto is trading in a short uptrend within a larger downtrend. Bitcoin will have to make a higher high above the $55,200 level for confirmation the downtrend is over.\nThe Dogecoin Chart:Dogecoin is trading in a steep downtrend but holding above a key support level of $0.197. The crypto's inside bar on Saturday demonstrates consolidation. If Dogecoin loses support at its key level it could fall toward the 16-cent mark.\nThe Ethereum Chart:Like Bitcoin, Ethereum may be working to reverse course into an uptrend but will need to shoot up above Thursday's high of $3182 for confirmation. Otherwise, the crypto could continue lower in its larger downtrend following Saturday's inside bar.","news_type":1},"isVote":1,"tweetType":1,"viewCount":56,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":148565979,"gmtCreate":1625990210591,"gmtModify":1633931045000,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Don't pin the hope too high, if they just barely meet the earning expectation, then people may sell it to take profit..[嘘]&nbsp;[嘘]&nbsp;","listText":"Don't pin the hope too high, if they just barely meet the earning expectation, then people may sell it to take profit..[嘘]&nbsp;[嘘]&nbsp;","text":"Don't pin the hope too high, if they just barely meet the earning expectation, then people may sell it to take profit..[嘘] [嘘]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/148565979","repostId":"1135090843","repostType":2,"repost":{"id":"1135090843","pubTimestamp":1625970902,"share":"https://www.laohu8.com/m/news/1135090843?lang=&edition=full","pubTime":"2021-07-11 10:35","market":"us","language":"en","title":"7 Earnings Reports to Watch Next Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1135090843","media":"InvestorPlace","summary":"Earnings reports will provide insight into how these companies are performing\nSource: Shutterstock\nT","content":"<p>Earnings reports will provide insight into how these companies are performing</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0d277b8ff1b6b6711ba0749313119f04\" tg-width=\"1024\" tg-height=\"576\"><span>Source: Shutterstock</span></p>\n<p>The major U.S. banks are due to report their latest earnings the week of July 12, and the results can be expected to dominate the financial news cycle. The earnings will provide insights into the health and momentum of the economy as they provide a read on both business and consumer spending. With the economy sprinting coming out of the Covid-19 pandemic, the big commercial and investment banks are expected toreport strong results.</p>\n<p>The banks are also expected to begin rewarding shareholders after the U.S. Federal Reserve recently cleared them to again payout dividends and buyback their own stock. Wall Street estimates forecast that the six biggest U.S. banks could&nbsp;return more than $140 billion&nbsp;to shareholders in coming months through dividends and share buybacks.</p>\n<p>Here are seven of the biggest American banks with earnings reports next week:</p>\n<ul>\n <li><b>JPMorgan Chase</b>(NYSE:<b><u>JPM</u></b>)</li>\n <li><b>Goldman Sachs</b>(NYSE:<b><u>GS</u></b>)</li>\n <li><b>Bank of America</b>(NYSE:<b><u>BAC</u></b>)</li>\n <li><b>Citigroup</b>(NYSE:<b><u>C</u></b>)</li>\n <li><b>Wells Fargo</b>(NYSE:<b><u>WFC</u></b>)</li>\n <li><b>Morgan Stanley</b>(NYSE:<b><u>MS</u></b>)</li>\n <li><b>U.S. Bancorp</b>(NYSE:<b><u>USB</u></b>)</li>\n</ul>\n<p><b>JPMorgan Chase (JPM)</b></p>\n<p>First out of the gate next week is the biggest U.S. bank, JPMorgan Chase. The financial conglomerate led by Jamie Dimon has generated headlines for its spate of recent acquisitions. The bank has&nbsp;made 33 acquisitions&nbsp;so far this year, its biggest spending spree in several years. The deals have mostly involved small foreign money managers and digital banks in countries such as England and Brazil.</p>\n<p>JPMorgan Chase has said that it is pursuing acquisitions to contend with an ongoing low-interest-rate environment and greater competition from financial technology (fintech) companies.</p>\n<p>The deals completed in the first half of this year are on par with all the deals JPMorgan Chase completed last year. JPM stock has risen this year along with the entire bank sector. Year-to-date, JPM stock is up 22% to a July 9 open of $153.05. In the past 12 months, the stock has increased 66%. In this year’s first quarter, JPMorgan Chase’s earnings increased 477% to $4.50 per share diluted and beat analyst estimates of $3.06 a share. Earnings were given a significant boost by $5.2 billion of net reserves that the bank had built up in 2020 during the pandemic.</p>\n<p>For the&nbsp;second-quarter results&nbsp;to be released on July 13, analysts are forecasting revenue of $30 billion and earnings per share (EPS) of $3.03.</p>\n<p><b>Goldman Sachs (GS)</b></p>\n<p>Leading investment bank Goldman Sachs also reports&nbsp;second-quarter results&nbsp;on July 13, and expectations are high for blockbuster earnings. The venerable Wall Street firm set the bar high earlier this year when it reported record first quarter results that blew away expectations. Fueled by a record amount of investment banking activity, Goldman Sachs reported first quarter revenues of $17.7 billion, way ahead of the $12.6 billion forecast by analysts. EPS for the bank came in at $18.60, destroying the $10.22 estimated by analysts and 498% higher than in the first quarter of 2020.</p>\n<p>Can Goldman do it again with its second-quarter results? The&nbsp;consensus among analysts&nbsp;is for the investment bank to report second-quarter EPS of $9.52 a share, for year-over-year growth of 52%. Should Goldman Sachs beat expectations by a wide margin, it will likely propel the company’s share price to new heights. In this year’s first half, GS stock rose 40% to its July 9 opening price of $366. In the past year, the stock has gained 77%.</p>\n<p>Despite the big run in the bank’s share price, analysts see further gains in store. The&nbsp;median price target&nbsp;on GS stock is $415, implying another 13% gain in coming months.</p>\n<p><b>Bank of America (BAC)</b></p>\n<p>The second-largest U.S. bank by assets, Bank of America, reports its&nbsp;latest quarterly numbers&nbsp;on July 14. And the lender has been signaling that Wall Street should expect solid second-quarter results. Chief Executive Officer Brian Moynihan has been saying publicly that Bank of America is emerging from the pandemic a stronger and more competitive financial institution, helped by higher capital ratios and higher reserves. In the first quarter, the bank reported record levels of deposits, investment flows and investment banking revenues.</p>\n<p>Bank of America attracted the attention of investors when it announced on June 28 that it will increase its common stock&nbsp;dividend by 17%&nbsp;to 21 cents per share for the third quarter of this year. This came after the bank announced a $25 billion share buyback plan in April. For the second quarter, Bank of America is&nbsp;expected to report&nbsp;EPS of 77 cents, more than doubling Q2 2020’s $0.37.</p>\n<p>In this year’s first quarter, Bank of America posted EPS of 86 cents, up 115% year-over-year and above the consensus forecast of 66 cents. First quarter revenues were up a slight 0.2% to $22.8 billion, beating analysts’ estimates of $22.13 billion. BAC stock has climbed 32% higher year-to-date to $39.65 a share as of July 9. In the past 12 months, the share price has increased 73%. While the stock&nbsp;pulled back in the middle of June, next week’s earnings could spark the next leg higher.</p>\n<p><b>Citigroup (C)</b></p>\n<p>On July 14, we’ll also get earnings from Citigroup. And the latest results come at a time when C stock has been struggling and, at its July 9 level of $66.73 a share, is starting to look a little undervalued compared to its peers.</p>\n<p>Citigroup’s share price is up 11% year-to-date and has risen 34% over the last 52 weeks. Those are decent returns, but they trail the other big banks featured in this article. In the past month, Citigroup’s share price has slumped 14%. The&nbsp;June drop&nbsp;came after the bank warned that its trading revenue will likely decline by 30% this year on weak deal volumes.</p>\n<p>Despite the downward guidance, analysts still expect Citigroup to report earnings growth for the second quarter of this year. The bank is forecast to post EPS of $1.91 next week, which would be a year-over-year increase of nearly 300%. However, revenues are expected to come in at $17.35 billion, which would be about 10% lower than the second quarter of 2020 revenue of $19.77 billion. Many analysts revised down their revenue forecasts after Citigroup warned of rising costs. Chief Financial Officer Mark Mason said on June 16 that he expects&nbsp;second-quarter expenses&nbsp;to increase by as much as $11.6 billion.</p>\n<p><b>Wells Fargo (WFC)</b></p>\n<p>San Francisco-based Wells Fargo, which reports earnings on July 14, recently dominated headlines after it announced that it is closing out all of its existing&nbsp;personal lines of credit&nbsp;and will no longer offer the financial product. Lines of credit typically give retail customers loans of $3,000 to $100,000 and is often used to consolidate higher-interest credit card debt, pay for home renovations and fund college educations.</p>\n<p>The news came as a jolt to Wells Fargo customers, who were informed by the bank that the credit line closures “may have an impact on your credit score.”</p>\n<p>Eliminating the lines of credit is the latest move by Wells Fargo as it reviews its operations coming out the pandemic. The steps taken to date seem to be winning approval from investors. WFC stock is one of the best performing among banks this year. So far this year, Wells Fargo stock has gained 44% and now trades at $43.18. The share price is up 77% over the last year.For its second quarter, analysts expect Wells Fargo to report EPS of 93 cents on $17.78 billion in revenues.</p>\n<p><b>Morgan Stanley (MS)</b></p>\n<p>Investment bank Morgan Stanley won praise from investors a few weeks back after it became the first Wall Street firm to increase its dividend payout after passing the U.S. Federal Reserve’s latest stress test. A day after getting the all clear from the central bank, Morgan Stanley announced that it is&nbsp;doubling its quarterly dividend&nbsp;to 70 cents per share starting in this year’s third quarter and spending $12 billion to buy back its own stock. The share repurchase program will run for the next four quarters.</p>\n<p>The positive news for shareholders helped to extend a rally in MS stock, which is now up 31% year-to-date at $87.40 a share, and up 79% over the past 12 months. Similar to rival investment bank Goldman Sachs, Morgan Stanley’s first quarter revenue toppled analyst expectations. For the&nbsp;first three months&nbsp;of this year, Morgan Stanley reported EPS of $2.22 a share, a substantial improvement over projections of $1.70. And the company’s revenue increased 61% in the first quarter to a record $15.7 billion, beating analysts’ estimates by $1.6 billion.</p>\n<p>For the second quarter&nbsp;reporting on July 15, analysts forecast that Morgan Stanley will report EPS of $1.65 on revenue of $13.96 billion.</p>\n<p><b>U.S. Bancorp (USB)</b></p>\n<p>Probably the least-known bank on this list is Minneapolis, Minnesota-based U.S. Bancorp. While it primarily operates in the Midwest, U.S. Bancorp is currently the fifth-largest American bank with assets approaching $500 billion. Often referred to as a“super regional bank”because of its size and performance, the lender is a&nbsp;long-term holding&nbsp;of legendary investor Warren Buffett’s&nbsp;<b>Berkshire Hathaway</b>(NYSE:<b><u>BRK.B</u></b>) holding company. Buffett currently has more than $8 billion invested in USB stock.</p>\n<p>Year-to-date, USB stock is up 22%, opening July 9 at $56.08 a share. In the past 12 months, the share price has climbed 60% higher. However, like the rest of the banking sector, U.S. Bancorp’s stock pulled back over the past month, dipping 6% on worries that inflation is abating and interest rates may remain at historic lows over the medium-term.</p>\n<p>As for its earnings on July 15, analysts expect the lender to&nbsp;report EPS of $1.12&nbsp;for the second quarter on revenues of $5.63 billion. In&nbsp;this year’s first quarter, U.S. Bancorp reported EPS of $1.45, beating consensus estimates of 96 cents. First quarter revenue came in at $5.47 billion compared to analysts’ expectations of $5.53 billion.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Earnings Reports to Watch Next Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Earnings Reports to Watch Next Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-11 10:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/earnings-reports-to-watch-next-week/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earnings reports will provide insight into how these companies are performing\nSource: Shutterstock\nThe major U.S. banks are due to report their latest earnings the week of July 12, and the results can...</p>\n\n<a href=\"https://investorplace.com/earnings-reports-to-watch-next-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WFC":"富国银行","C":"花旗","BAC":"美国银行","MS":"摩根士丹利","JPM":"摩根大通","USB":"美国合众银行","GS":"高盛"},"source_url":"https://investorplace.com/earnings-reports-to-watch-next-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135090843","content_text":"Earnings reports will provide insight into how these companies are performing\nSource: Shutterstock\nThe major U.S. banks are due to report their latest earnings the week of July 12, and the results can be expected to dominate the financial news cycle. The earnings will provide insights into the health and momentum of the economy as they provide a read on both business and consumer spending. With the economy sprinting coming out of the Covid-19 pandemic, the big commercial and investment banks are expected toreport strong results.\nThe banks are also expected to begin rewarding shareholders after the U.S. Federal Reserve recently cleared them to again payout dividends and buyback their own stock. Wall Street estimates forecast that the six biggest U.S. banks could return more than $140 billion to shareholders in coming months through dividends and share buybacks.\nHere are seven of the biggest American banks with earnings reports next week:\n\nJPMorgan Chase(NYSE:JPM)\nGoldman Sachs(NYSE:GS)\nBank of America(NYSE:BAC)\nCitigroup(NYSE:C)\nWells Fargo(NYSE:WFC)\nMorgan Stanley(NYSE:MS)\nU.S. Bancorp(NYSE:USB)\n\nJPMorgan Chase (JPM)\nFirst out of the gate next week is the biggest U.S. bank, JPMorgan Chase. The financial conglomerate led by Jamie Dimon has generated headlines for its spate of recent acquisitions. The bank has made 33 acquisitions so far this year, its biggest spending spree in several years. The deals have mostly involved small foreign money managers and digital banks in countries such as England and Brazil.\nJPMorgan Chase has said that it is pursuing acquisitions to contend with an ongoing low-interest-rate environment and greater competition from financial technology (fintech) companies.\nThe deals completed in the first half of this year are on par with all the deals JPMorgan Chase completed last year. JPM stock has risen this year along with the entire bank sector. Year-to-date, JPM stock is up 22% to a July 9 open of $153.05. In the past 12 months, the stock has increased 66%. In this year’s first quarter, JPMorgan Chase’s earnings increased 477% to $4.50 per share diluted and beat analyst estimates of $3.06 a share. Earnings were given a significant boost by $5.2 billion of net reserves that the bank had built up in 2020 during the pandemic.\nFor the second-quarter results to be released on July 13, analysts are forecasting revenue of $30 billion and earnings per share (EPS) of $3.03.\nGoldman Sachs (GS)\nLeading investment bank Goldman Sachs also reports second-quarter results on July 13, and expectations are high for blockbuster earnings. The venerable Wall Street firm set the bar high earlier this year when it reported record first quarter results that blew away expectations. Fueled by a record amount of investment banking activity, Goldman Sachs reported first quarter revenues of $17.7 billion, way ahead of the $12.6 billion forecast by analysts. EPS for the bank came in at $18.60, destroying the $10.22 estimated by analysts and 498% higher than in the first quarter of 2020.\nCan Goldman do it again with its second-quarter results? The consensus among analysts is for the investment bank to report second-quarter EPS of $9.52 a share, for year-over-year growth of 52%. Should Goldman Sachs beat expectations by a wide margin, it will likely propel the company’s share price to new heights. In this year’s first half, GS stock rose 40% to its July 9 opening price of $366. In the past year, the stock has gained 77%.\nDespite the big run in the bank’s share price, analysts see further gains in store. The median price target on GS stock is $415, implying another 13% gain in coming months.\nBank of America (BAC)\nThe second-largest U.S. bank by assets, Bank of America, reports its latest quarterly numbers on July 14. And the lender has been signaling that Wall Street should expect solid second-quarter results. Chief Executive Officer Brian Moynihan has been saying publicly that Bank of America is emerging from the pandemic a stronger and more competitive financial institution, helped by higher capital ratios and higher reserves. In the first quarter, the bank reported record levels of deposits, investment flows and investment banking revenues.\nBank of America attracted the attention of investors when it announced on June 28 that it will increase its common stock dividend by 17% to 21 cents per share for the third quarter of this year. This came after the bank announced a $25 billion share buyback plan in April. For the second quarter, Bank of America is expected to report EPS of 77 cents, more than doubling Q2 2020’s $0.37.\nIn this year’s first quarter, Bank of America posted EPS of 86 cents, up 115% year-over-year and above the consensus forecast of 66 cents. First quarter revenues were up a slight 0.2% to $22.8 billion, beating analysts’ estimates of $22.13 billion. BAC stock has climbed 32% higher year-to-date to $39.65 a share as of July 9. In the past 12 months, the share price has increased 73%. While the stock pulled back in the middle of June, next week’s earnings could spark the next leg higher.\nCitigroup (C)\nOn July 14, we’ll also get earnings from Citigroup. And the latest results come at a time when C stock has been struggling and, at its July 9 level of $66.73 a share, is starting to look a little undervalued compared to its peers.\nCitigroup’s share price is up 11% year-to-date and has risen 34% over the last 52 weeks. Those are decent returns, but they trail the other big banks featured in this article. In the past month, Citigroup’s share price has slumped 14%. The June drop came after the bank warned that its trading revenue will likely decline by 30% this year on weak deal volumes.\nDespite the downward guidance, analysts still expect Citigroup to report earnings growth for the second quarter of this year. The bank is forecast to post EPS of $1.91 next week, which would be a year-over-year increase of nearly 300%. However, revenues are expected to come in at $17.35 billion, which would be about 10% lower than the second quarter of 2020 revenue of $19.77 billion. Many analysts revised down their revenue forecasts after Citigroup warned of rising costs. Chief Financial Officer Mark Mason said on June 16 that he expects second-quarter expenses to increase by as much as $11.6 billion.\nWells Fargo (WFC)\nSan Francisco-based Wells Fargo, which reports earnings on July 14, recently dominated headlines after it announced that it is closing out all of its existing personal lines of credit and will no longer offer the financial product. Lines of credit typically give retail customers loans of $3,000 to $100,000 and is often used to consolidate higher-interest credit card debt, pay for home renovations and fund college educations.\nThe news came as a jolt to Wells Fargo customers, who were informed by the bank that the credit line closures “may have an impact on your credit score.”\nEliminating the lines of credit is the latest move by Wells Fargo as it reviews its operations coming out the pandemic. The steps taken to date seem to be winning approval from investors. WFC stock is one of the best performing among banks this year. So far this year, Wells Fargo stock has gained 44% and now trades at $43.18. The share price is up 77% over the last year.For its second quarter, analysts expect Wells Fargo to report EPS of 93 cents on $17.78 billion in revenues.\nMorgan Stanley (MS)\nInvestment bank Morgan Stanley won praise from investors a few weeks back after it became the first Wall Street firm to increase its dividend payout after passing the U.S. Federal Reserve’s latest stress test. A day after getting the all clear from the central bank, Morgan Stanley announced that it is doubling its quarterly dividend to 70 cents per share starting in this year’s third quarter and spending $12 billion to buy back its own stock. The share repurchase program will run for the next four quarters.\nThe positive news for shareholders helped to extend a rally in MS stock, which is now up 31% year-to-date at $87.40 a share, and up 79% over the past 12 months. Similar to rival investment bank Goldman Sachs, Morgan Stanley’s first quarter revenue toppled analyst expectations. For the first three months of this year, Morgan Stanley reported EPS of $2.22 a share, a substantial improvement over projections of $1.70. And the company’s revenue increased 61% in the first quarter to a record $15.7 billion, beating analysts’ estimates by $1.6 billion.\nFor the second quarter reporting on July 15, analysts forecast that Morgan Stanley will report EPS of $1.65 on revenue of $13.96 billion.\nU.S. Bancorp (USB)\nProbably the least-known bank on this list is Minneapolis, Minnesota-based U.S. Bancorp. While it primarily operates in the Midwest, U.S. Bancorp is currently the fifth-largest American bank with assets approaching $500 billion. Often referred to as a“super regional bank”because of its size and performance, the lender is a long-term holding of legendary investor Warren Buffett’s Berkshire Hathaway(NYSE:BRK.B) holding company. Buffett currently has more than $8 billion invested in USB stock.\nYear-to-date, USB stock is up 22%, opening July 9 at $56.08 a share. In the past 12 months, the share price has climbed 60% higher. However, like the rest of the banking sector, U.S. Bancorp’s stock pulled back over the past month, dipping 6% on worries that inflation is abating and interest rates may remain at historic lows over the medium-term.\nAs for its earnings on July 15, analysts expect the lender to report EPS of $1.12 for the second quarter on revenues of $5.63 billion. In this year’s first quarter, U.S. Bancorp reported EPS of $1.45, beating consensus estimates of 96 cents. First quarter revenue came in at $5.47 billion compared to analysts’ expectations of $5.53 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":16,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":152773332,"gmtCreate":1625360980526,"gmtModify":1633941333445,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"This is the pace that investors wanna see..[微笑]&nbsp;[微笑]&nbsp;","listText":"This is the pace that investors wanna see..[微笑]&nbsp;[微笑]&nbsp;","text":"This is the pace that investors wanna see..[微笑] [微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/152773332","repostId":"1165340887","repostType":4,"isVote":1,"tweetType":1,"viewCount":29,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":353194519,"gmtCreate":1616467275431,"gmtModify":1634525670378,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Let't rock and roll[鬼脸]&nbsp;[可爱]&nbsp;","listText":"Let't rock and roll[鬼脸]&nbsp;[可爱]&nbsp;","text":"Let't rock and roll[鬼脸] [可爱]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/353194519","repostId":"1137089057","repostType":4,"repost":{"id":"1137089057","pubTimestamp":1616467170,"share":"https://www.laohu8.com/m/news/1137089057?lang=&edition=full","pubTime":"2021-03-23 10:39","market":"us","language":"en","title":"Will It Really Take 4 Years for the Nasdaq's Hottest Stock to Hit $3,000 per Share?","url":"https://stock-news.laohu8.com/highlight/detail?id=1137089057","media":"fool","summary":"The stock market moved higher on Monday, and theNasdaq Compositeled the way higher. As of around 2 p.m. EDT, theNasdaqwas up about 1.5%, easily outpacing the performance of other major market benchmarks. The move largely reflected a return of confidence in the Federal Reserve's ability to manage economic growth going forward, as interest rates on Treasury bonds moved lower after a prolonged rise over the past several months.Tesla gets a boost from the world's most popular investment manager. A p","content":"<p>The stock market moved higher on Monday, and the<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)led the way higher. As of around 2 p.m. EDT, theNasdaqwas up about 1.5%, easily outpacing the performance of other major market benchmarks. The move largely reflected a return of confidence in the Federal Reserve's ability to manage economic growth going forward, as interest rates on Treasury bonds moved lower after a prolonged rise over the past several months.</p>\n<p>One of the biggest contributors to the Nasdaq's performance over the past year has been<b>Tesla</b>(NASDAQ:TSLA). The electric vehicle pioneer's stock is up more than 700% since March 2020, and that's even after the stock lost more than a third of its value earlier this month from its February highs. Despite that strong performance, though, one big fan of Tesla stock believes there's a lot more upside left -- and she's calling for the stock to reach $3,000 per share by 2025. While that might seem like an ambitious timeframe for some, others have to wonder whether seemingly outlandish predictions for Tesla might prove not to be outlandish<i>enough</i>to reflect what the next several years could bring for the Elon Musk-led innovator.</p>\n<p>Tesla gets a boost from the world's most popular investment manager</p>\n<p>Shares of Tesla were up almost 6% on Monday, challenging the $700 per share mark. However, that's just a tiny portion of the gains in store for the automaker if Cathie Wood, chief investment officer and founder of the red-hot investment management company ARK Invest, is right about her investing thesis.</p>\n<p>It's not the first time ARK Invest has waxed bullish on Tesla. It was only last year that the investment management company set a$7,000 per share price target on Tesla by 2024-- now $1,400 after the automaker's 5-for-1 stock split last summer. With its shares having risen to $900 per share in early 2021, that level seemed well within reach after a stellar 2020 for Tesla stock.</p>\n<p>The methodology behind ARK Invest's call revealed some of the high expectations it has for Tesla's business. In the next five years, ARK Invest sees Tesla selling between 5 million and 10 million vehicles per year, up 10 to 20 times from the nearly 500,000 it sold in 2020. Average selling price should continue to fall as innovation makes production cheaper and Tesla concentrates more on mass-market EVs. That would potentially produce EV-related sales of between $234 billion and $367 billion annually.</p>\n<p>ARK Invest also sees some ancillary businesses potentially taking off. Wood has been a proponent of Tesla getting into the ride-hailing business, and the bullish analysis calls for Tesla to bring in $327 billion by 2025 from self-driving vehicles picking up passengers.</p>\n<p>A price of $3,000 per share is only the expected value based on ARK Invest's analysis. The company sees a 75% chance of the stock climbing to at least $1,500 per share by 2025, and a 25% chance of the share price eclipsing the $4,000 mark.</p>\n<p>Why it could happen faster</p>\n<p>It's important to note, though, that ARK Invest didn't even take into consideration some parts of Tesla's business. It didn't try to model the work that Tesla is doing in energy storage, for instance, or in the solar industry. That leaves out the very real potential that Tesla's work in automotive battery technology could have wide-ranging applications far beyond the auto industry.</p>\n<p>In addition, ARK Invest left out any potential returns fromTesla's cryptocurrency investments. If crypto continues to rise at the pace it has previously, then it could eventually make up a much larger portion of Tesla's balance sheet than the $1.5 billion investment it initially made.</p>\n<p>To expect Tesla to become the most valuable company in the world by far is an ambitious call. But bulls have been right about the electric vehicle pioneer so far, and trying to go against the stock's set of passionate followers has turned to be a bad bet for years. Indeed, at the rate it's risen lately, Tesla could hit $3,000 per share a lot sooner than 2025 if things keep going its way.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will It Really Take 4 Years for the Nasdaq's Hottest Stock to Hit $3,000 per Share?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill It Really Take 4 Years for the Nasdaq's Hottest Stock to Hit $3,000 per Share?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-23 10:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/22/will-really-take-4-years-nasdaq-hottest-stock-3000/><strong>fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market moved higher on Monday, and theNasdaq Composite(NASDAQINDEX:^IXIC)led the way higher. As of around 2 p.m. EDT, theNasdaqwas up about 1.5%, easily outpacing the performance of other ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/22/will-really-take-4-years-nasdaq-hottest-stock-3000/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/d1f099f6724852eed80c0925003dfca8","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.fool.com/investing/2021/03/22/will-really-take-4-years-nasdaq-hottest-stock-3000/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137089057","content_text":"The stock market moved higher on Monday, and theNasdaq Composite(NASDAQINDEX:^IXIC)led the way higher. As of around 2 p.m. EDT, theNasdaqwas up about 1.5%, easily outpacing the performance of other major market benchmarks. The move largely reflected a return of confidence in the Federal Reserve's ability to manage economic growth going forward, as interest rates on Treasury bonds moved lower after a prolonged rise over the past several months.\nOne of the biggest contributors to the Nasdaq's performance over the past year has beenTesla(NASDAQ:TSLA). The electric vehicle pioneer's stock is up more than 700% since March 2020, and that's even after the stock lost more than a third of its value earlier this month from its February highs. Despite that strong performance, though, one big fan of Tesla stock believes there's a lot more upside left -- and she's calling for the stock to reach $3,000 per share by 2025. While that might seem like an ambitious timeframe for some, others have to wonder whether seemingly outlandish predictions for Tesla might prove not to be outlandishenoughto reflect what the next several years could bring for the Elon Musk-led innovator.\nTesla gets a boost from the world's most popular investment manager\nShares of Tesla were up almost 6% on Monday, challenging the $700 per share mark. However, that's just a tiny portion of the gains in store for the automaker if Cathie Wood, chief investment officer and founder of the red-hot investment management company ARK Invest, is right about her investing thesis.\nIt's not the first time ARK Invest has waxed bullish on Tesla. It was only last year that the investment management company set a$7,000 per share price target on Tesla by 2024-- now $1,400 after the automaker's 5-for-1 stock split last summer. With its shares having risen to $900 per share in early 2021, that level seemed well within reach after a stellar 2020 for Tesla stock.\nThe methodology behind ARK Invest's call revealed some of the high expectations it has for Tesla's business. In the next five years, ARK Invest sees Tesla selling between 5 million and 10 million vehicles per year, up 10 to 20 times from the nearly 500,000 it sold in 2020. Average selling price should continue to fall as innovation makes production cheaper and Tesla concentrates more on mass-market EVs. That would potentially produce EV-related sales of between $234 billion and $367 billion annually.\nARK Invest also sees some ancillary businesses potentially taking off. Wood has been a proponent of Tesla getting into the ride-hailing business, and the bullish analysis calls for Tesla to bring in $327 billion by 2025 from self-driving vehicles picking up passengers.\nA price of $3,000 per share is only the expected value based on ARK Invest's analysis. The company sees a 75% chance of the stock climbing to at least $1,500 per share by 2025, and a 25% chance of the share price eclipsing the $4,000 mark.\nWhy it could happen faster\nIt's important to note, though, that ARK Invest didn't even take into consideration some parts of Tesla's business. It didn't try to model the work that Tesla is doing in energy storage, for instance, or in the solar industry. That leaves out the very real potential that Tesla's work in automotive battery technology could have wide-ranging applications far beyond the auto industry.\nIn addition, ARK Invest left out any potential returns fromTesla's cryptocurrency investments. If crypto continues to rise at the pace it has previously, then it could eventually make up a much larger portion of Tesla's balance sheet than the $1.5 billion investment it initially made.\nTo expect Tesla to become the most valuable company in the world by far is an ambitious call. But bulls have been right about the electric vehicle pioneer so far, and trying to go against the stock's set of passionate followers has turned to be a bad bet for years. Indeed, at the rate it's risen lately, Tesla could hit $3,000 per share a lot sooner than 2025 if things keep going its way.","news_type":1},"isVote":1,"tweetType":1,"viewCount":53,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605534085,"gmtCreate":1639188985261,"gmtModify":1639188985987,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Tapering and rising interest rate will come sooner I guess","listText":"Tapering and rising interest rate will come sooner I guess","text":"Tapering and rising interest rate will come sooner I guess","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/605534085","repostId":"2190767366","repostType":4,"isVote":1,"tweetType":1,"viewCount":306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873615274,"gmtCreate":1636937225400,"gmtModify":1636937225740,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"There are both good and bad, but I guess good outweighs the bad...","listText":"There are both good and bad, but I guess good outweighs the bad...","text":"There are both good and bad, but I guess good outweighs the bad...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873615274","repostId":"1178164317","repostType":4,"repost":{"id":"1178164317","pubTimestamp":1636936020,"share":"https://www.laohu8.com/m/news/1178164317?lang=&edition=full","pubTime":"2021-11-15 08:27","market":"us","language":"en","title":"GE and JNJ Aren't the Only Aging Companies That Could Benefit From a Breakup","url":"https://stock-news.laohu8.com/highlight/detail?id=1178164317","media":"Thestreet","summary":"After years of turmoil and a valiant effort by its latest CEO Larry Culp, General Electric (GE) fina","content":"<p>After years of turmoil and a valiant effort by its latest CEO Larry Culp, General Electric (GE) finally gave up in its efforts to salvage its broad-reaching business as a singular unit.</p>\n<p>The company has consistently spun off numerous assets across the sprawling conglomerate in recent years to lessen its debt load. Perhaps most important was a $20 billion deal to ship its biopharmaceutical business to Danaher (DHR) in 2020. Yet, it appears the moves were not enough to satisfy Culp's ambitious recovery goals for the once-great industrial giant.</p>\n<p>\"The world demands-and deserves-we bring our best to solve the biggest challenges in flight, healthcare, and energy,\" Culp said in a statement on Tuesday. \"By creating three industry-leading, global public companies, each can benefit from greater focus, tailored capital allocation, and strategic flexibility to drive long-term growth and value for customers, investors, and employees. We are putting our technology expertise, leadership, and global reach to work to better serve our customers.\"</p>\n<p>Similarly, the lawsuit-besieged Johnson &amp; Johnson (JNJ)announced it would spin off its consumer health division&nbsp;from its higher growth pharmaceutical and medical devices divisions in the coming two years.</p>\n<p>Judging by the&nbsp;jump in GE stock after the announcement&nbsp;and the early jolt to Johnson &amp; Johnson stock after its announcement Friday<u>,</u>the market certainly looks as though it was offering its initial approval for the streamlining of separate companies. Still, a few questions quickly come to mind.</p>\n<p>First, is this indeed a deft move by management in both cases and therefore deserving of the share-price reaction? And if so, are there more companies that could benefit from following the example set by both of these storied companies?</p>\n<p><b>Better After a Breakup?</b></p>\n<p>The first line of questioning is one of whether or not two or three firms are truly better than one.</p>\n<p>On paper, it would certainly appear to be so. As of Thursday's market open, GE touted a valuation of about $119 billion as a total entity. However, when broken into constituent parts, RBC Capital Markets analyst Deane Dray suggested up to a 20% upside for investors. Judging by company metrics and projections, it could well be even higher.</p>\n<p>Also, each of the spun-off GE units will be less encumbered by the debt of their former counterparts within the broader company, especially as asset sales in recent years alleviate debt and pension issues. Further, future deals are more likely to reach approval based upon diminished antitrust risk, opening a much wider world of opportunity for investors in the streamlined companies.</p>\n<p>The logic is very much the same for Johnson &amp; Johnson as its pharmaceutical business breaks free from the burdensome troubles of&nbsp;lawsuits over talcum-powder&nbsp;products as well as low-margin medicines like Tylenol. Separation is seen as a key step toward unlocking innovation.</p>\n<p>\"For the new Johnson &amp; Johnson, this planned separation underscores our focus on delivering industry-leading biopharmaceutical and medical device innovation and technology with the goal of bringing new solutions to market for patients and healthcare systems, while creating sustainable value for shareholders,\" CEO Alex Gorsky explained in a statement. \"We believe that the New Consumer Health Company would be a global leader across attractive and growing consumer health categories, and a streamlined and targeted corporate structure would provide it with the agility and flexibility to grow its iconic portfolio of brands and innovate new products.\"</p>\n<p>To be sure, these targets and optimistic angles assume a rosy trajectory for each of the newly formed firms. As the example of DowDupont (now Dupont (DD) , Dow Inc. (DOW) , and Corteva (CTVA) ) shows, splitting up historic firms with sprawling business is not always a process that progresses precisely to plan.</p>\n<p>Since splitting, the two storied industrial companies, once combined into one mega-conglomerate, have not had much success.</p>\n<p>\"New Dow will be well positioned to drive best-in-class financial performance and shareholder returns,\" Dow CEO Jim Fitterling said ahead of the firm's 2019 spinoff to a standalone firm. \"We have a focused playbook of cost and growth drivers, clear and disciplined capital allocation priorities and a strong balance sheet. Our path to shareholder value creation is straightforward and in our control.\"</p>\n<p>These pronouncements are very much in line with what GE has said of each of its planned new standalone entities. Also, in a move very much reminiscent of GE's quarterly results in recent years, the pronouncement promised much more than what has actually been delivered.</p>\n<p>Since it's spinoff was official in April 2019, DOW stock has marked a less than 10% gain. Meanwhile, the S&amp;P has risen over 60% over the same period.</p>\n<p><b>An Example to Follow?</b></p>\n<p>Still, assuming things do go well post-breakup, these moves could serve as a benchmark for other bigger, older, and perhaps bloated companies. At the very least, this is the logic adopted not only by aging and perhaps overcomplicated American conglomerates like GE and Johnson &amp; Johnson, but also the nearly 150-year-old Japanese giant Toshiba (TOSBF) . In short, it looks as though a trend is taking hold.</p>\n<p>\"Companies that have very diversified portfolios continue to dilute the value to the shareholders,\" David Braun, CEO of M&amp;A advisory firm Capstone Strategic, told Real Money. \"We are in an era where technology and access to capital are different things. A conglomerate is going to have trouble competing.\"</p>\n<p>He suggested that Emerson Electric (EMR) and Berkshire Hathaway (BRK.A) &nbsp; (BRK.B) are two companies that could likely benefit from a similar breakup.</p>\n<p>\"They continue to stockpile excess cash they cannot deploy,\" Braun added, voicing the drawbacks of the behemoth business. \"I'm not sure they benefit from that model any longer.\"</p>\n<p>On the former, he is far from the first to suggest such a move. RBC's Deane Dray has actually been calling for such a breakup for a few years, alongside 3M (MMM) and Roper Technologies (ROP) , firms he also believes could benefit from being a bit less bulky.</p>\n<p>\"We believe the pendulum is still swinging towards the 'urge to demerge' trend,\" he wrote in a note on Tuesday. \"GE's announcement today could embolden the boards of several other multi-industry companies to move ahead on more aggressive portfolio simplification moves, including Emerson, Roper Technologies and 3M.\"</p>\n<p>As far back as 2019, Dray suggested a breakup of Emerson's automation and commercial divisions could be a boon for shareholders. While the stock has been on a roll since the pandemic began, such a breakup has already been intensely considered by management. In early February, Emerson announced it would not pursue a split \"unless a major strategic acquisition catalyst is actioned.\"</p>\n<p>At the least, if such a catalyst is to appear the company is clearly willing to consider such an option.</p>\n<p>For Berkshire, it is eminently unlikely that any moves come while both Warren Buffett and Charlie Munger helm the conglomerate.&nbsp;But prospects for such a breakup could take many forms considering the business spans industries from insurance to construction to railroads. As such, attempting to size up a form that such a move might take is nearly impossible to forecast.</p>\n<p>Finally, the prospects of a 3M breakup are certainly not out of the question.</p>\n<p>Investors in the storied firm are understandably frustrated. Long-term shareholders have seen the stock stagnate over the past five years, marking a basically flat return even after shares were buoyed by demand for PPE and healthcare equipment that the firm manufactured during the pandemic. Looking back on the boost to the shares, many might have been happier with a pure-play option for healthcare and protective equipment rather than a company also weighed down by industrial, transportation, and consumer segments.</p>\n<p>Toward this end, the company may have already telegraphed its intention to move toward breaking up. In March 2019, the company divided its business into four units. The units, entitled safety &amp; industrial, transportation &amp; electronics, healthcare, and consumer respectively, were created in order to focus the business.</p>\n<p>\"We are continuing to advance 3M into the future, and today's actions will strengthen our ability to meet the fast-moving needs of our customers,\" 3M CEO Mike Roman said at the time. \"Our new alignment will leverage our business transformation progress, accelerate growth and deliver greater operational efficiencies.\"</p>\n<p>As operational efficiencies have not materialized to the point of elevating the share price, it is not unreasonable to ask questions as to why separate businesses might further tap into the desired efficiency. In short, the healthcare business might be stronger if it was no longer adhered to a scotch tape and post-it manufacturer and vice versa.</p>\n<p>In the end, if the pursuit of separate businesses proves successful in each of the current experiments under way, the lesson may be that bigger is not always better. For investors, it might also open a number of pure-play options that provide a better investment than their parent companies do at present.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GE and JNJ Aren't the Only Aging Companies That Could Benefit From a Breakup</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGE and JNJ Aren't the Only Aging Companies That Could Benefit From a Breakup\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 08:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://realmoney.thestreet.com/investing/stocks/ge-isn-t-the-only-aging-company-that-could-benefit-from-a-breakup-15830176?puc=yahoo&cm_ven=YAHOO><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After years of turmoil and a valiant effort by its latest CEO Larry Culp, General Electric (GE) finally gave up in its efforts to salvage its broad-reaching business as a singular unit.\nThe company ...</p>\n\n<a href=\"https://realmoney.thestreet.com/investing/stocks/ge-isn-t-the-only-aging-company-that-could-benefit-from-a-breakup-15830176?puc=yahoo&cm_ven=YAHOO\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","GE":"GE航空航天"},"source_url":"https://realmoney.thestreet.com/investing/stocks/ge-isn-t-the-only-aging-company-that-could-benefit-from-a-breakup-15830176?puc=yahoo&cm_ven=YAHOO","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178164317","content_text":"After years of turmoil and a valiant effort by its latest CEO Larry Culp, General Electric (GE) finally gave up in its efforts to salvage its broad-reaching business as a singular unit.\nThe company has consistently spun off numerous assets across the sprawling conglomerate in recent years to lessen its debt load. Perhaps most important was a $20 billion deal to ship its biopharmaceutical business to Danaher (DHR) in 2020. Yet, it appears the moves were not enough to satisfy Culp's ambitious recovery goals for the once-great industrial giant.\n\"The world demands-and deserves-we bring our best to solve the biggest challenges in flight, healthcare, and energy,\" Culp said in a statement on Tuesday. \"By creating three industry-leading, global public companies, each can benefit from greater focus, tailored capital allocation, and strategic flexibility to drive long-term growth and value for customers, investors, and employees. We are putting our technology expertise, leadership, and global reach to work to better serve our customers.\"\nSimilarly, the lawsuit-besieged Johnson & Johnson (JNJ)announced it would spin off its consumer health division from its higher growth pharmaceutical and medical devices divisions in the coming two years.\nJudging by the jump in GE stock after the announcement and the early jolt to Johnson & Johnson stock after its announcement Friday,the market certainly looks as though it was offering its initial approval for the streamlining of separate companies. Still, a few questions quickly come to mind.\nFirst, is this indeed a deft move by management in both cases and therefore deserving of the share-price reaction? And if so, are there more companies that could benefit from following the example set by both of these storied companies?\nBetter After a Breakup?\nThe first line of questioning is one of whether or not two or three firms are truly better than one.\nOn paper, it would certainly appear to be so. As of Thursday's market open, GE touted a valuation of about $119 billion as a total entity. However, when broken into constituent parts, RBC Capital Markets analyst Deane Dray suggested up to a 20% upside for investors. Judging by company metrics and projections, it could well be even higher.\nAlso, each of the spun-off GE units will be less encumbered by the debt of their former counterparts within the broader company, especially as asset sales in recent years alleviate debt and pension issues. Further, future deals are more likely to reach approval based upon diminished antitrust risk, opening a much wider world of opportunity for investors in the streamlined companies.\nThe logic is very much the same for Johnson & Johnson as its pharmaceutical business breaks free from the burdensome troubles of lawsuits over talcum-powder products as well as low-margin medicines like Tylenol. Separation is seen as a key step toward unlocking innovation.\n\"For the new Johnson & Johnson, this planned separation underscores our focus on delivering industry-leading biopharmaceutical and medical device innovation and technology with the goal of bringing new solutions to market for patients and healthcare systems, while creating sustainable value for shareholders,\" CEO Alex Gorsky explained in a statement. \"We believe that the New Consumer Health Company would be a global leader across attractive and growing consumer health categories, and a streamlined and targeted corporate structure would provide it with the agility and flexibility to grow its iconic portfolio of brands and innovate new products.\"\nTo be sure, these targets and optimistic angles assume a rosy trajectory for each of the newly formed firms. As the example of DowDupont (now Dupont (DD) , Dow Inc. (DOW) , and Corteva (CTVA) ) shows, splitting up historic firms with sprawling business is not always a process that progresses precisely to plan.\nSince splitting, the two storied industrial companies, once combined into one mega-conglomerate, have not had much success.\n\"New Dow will be well positioned to drive best-in-class financial performance and shareholder returns,\" Dow CEO Jim Fitterling said ahead of the firm's 2019 spinoff to a standalone firm. \"We have a focused playbook of cost and growth drivers, clear and disciplined capital allocation priorities and a strong balance sheet. Our path to shareholder value creation is straightforward and in our control.\"\nThese pronouncements are very much in line with what GE has said of each of its planned new standalone entities. Also, in a move very much reminiscent of GE's quarterly results in recent years, the pronouncement promised much more than what has actually been delivered.\nSince it's spinoff was official in April 2019, DOW stock has marked a less than 10% gain. Meanwhile, the S&P has risen over 60% over the same period.\nAn Example to Follow?\nStill, assuming things do go well post-breakup, these moves could serve as a benchmark for other bigger, older, and perhaps bloated companies. At the very least, this is the logic adopted not only by aging and perhaps overcomplicated American conglomerates like GE and Johnson & Johnson, but also the nearly 150-year-old Japanese giant Toshiba (TOSBF) . In short, it looks as though a trend is taking hold.\n\"Companies that have very diversified portfolios continue to dilute the value to the shareholders,\" David Braun, CEO of M&A advisory firm Capstone Strategic, told Real Money. \"We are in an era where technology and access to capital are different things. A conglomerate is going to have trouble competing.\"\nHe suggested that Emerson Electric (EMR) and Berkshire Hathaway (BRK.A)   (BRK.B) are two companies that could likely benefit from a similar breakup.\n\"They continue to stockpile excess cash they cannot deploy,\" Braun added, voicing the drawbacks of the behemoth business. \"I'm not sure they benefit from that model any longer.\"\nOn the former, he is far from the first to suggest such a move. RBC's Deane Dray has actually been calling for such a breakup for a few years, alongside 3M (MMM) and Roper Technologies (ROP) , firms he also believes could benefit from being a bit less bulky.\n\"We believe the pendulum is still swinging towards the 'urge to demerge' trend,\" he wrote in a note on Tuesday. \"GE's announcement today could embolden the boards of several other multi-industry companies to move ahead on more aggressive portfolio simplification moves, including Emerson, Roper Technologies and 3M.\"\nAs far back as 2019, Dray suggested a breakup of Emerson's automation and commercial divisions could be a boon for shareholders. While the stock has been on a roll since the pandemic began, such a breakup has already been intensely considered by management. In early February, Emerson announced it would not pursue a split \"unless a major strategic acquisition catalyst is actioned.\"\nAt the least, if such a catalyst is to appear the company is clearly willing to consider such an option.\nFor Berkshire, it is eminently unlikely that any moves come while both Warren Buffett and Charlie Munger helm the conglomerate. But prospects for such a breakup could take many forms considering the business spans industries from insurance to construction to railroads. As such, attempting to size up a form that such a move might take is nearly impossible to forecast.\nFinally, the prospects of a 3M breakup are certainly not out of the question.\nInvestors in the storied firm are understandably frustrated. Long-term shareholders have seen the stock stagnate over the past five years, marking a basically flat return even after shares were buoyed by demand for PPE and healthcare equipment that the firm manufactured during the pandemic. Looking back on the boost to the shares, many might have been happier with a pure-play option for healthcare and protective equipment rather than a company also weighed down by industrial, transportation, and consumer segments.\nToward this end, the company may have already telegraphed its intention to move toward breaking up. In March 2019, the company divided its business into four units. The units, entitled safety & industrial, transportation & electronics, healthcare, and consumer respectively, were created in order to focus the business.\n\"We are continuing to advance 3M into the future, and today's actions will strengthen our ability to meet the fast-moving needs of our customers,\" 3M CEO Mike Roman said at the time. \"Our new alignment will leverage our business transformation progress, accelerate growth and deliver greater operational efficiencies.\"\nAs operational efficiencies have not materialized to the point of elevating the share price, it is not unreasonable to ask questions as to why separate businesses might further tap into the desired efficiency. In short, the healthcare business might be stronger if it was no longer adhered to a scotch tape and post-it manufacturer and vice versa.\nIn the end, if the pursuit of separate businesses proves successful in each of the current experiments under way, the lesson may be that bigger is not always better. For investors, it might also open a number of pure-play options that provide a better investment than their parent companies do at present.","news_type":1},"isVote":1,"tweetType":1,"viewCount":85,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845973232,"gmtCreate":1636273064358,"gmtModify":1636273065380,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"With more and more business is migrating to cloud..the cybersecurity is getting more important..","listText":"With more and more business is migrating to cloud..the cybersecurity is getting more important..","text":"With more and more business is migrating to cloud..the cybersecurity is getting more important..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/845973232","repostId":"2181740934","repostType":4,"repost":{"id":"2181740934","pubTimestamp":1636261200,"share":"https://www.laohu8.com/m/news/2181740934?lang=&edition=full","pubTime":"2021-11-07 13:00","market":"us","language":"en","title":"SolarWinds investors allege board knew about cyber risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2181740934","media":"The Straits Times","summary":"NEW YORK (REUTERS) - SolarWinds investors have sued the software company's directors, alleging they ","content":"<div>\n<p>NEW YORK (REUTERS) - SolarWinds investors have sued the software company's directors, alleging they knew about and failed to monitor cyber-security risks to the company ahead of a breach that created ...</p>\n\n<a href=\"http://www.straitstimes.com/tech/tech-news/solarwinds-investors-allege-board-knew-about-cyber-risks\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SolarWinds investors allege board knew about cyber risks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSolarWinds investors allege board knew about cyber risks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-07 13:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/tech/tech-news/solarwinds-investors-allege-board-knew-about-cyber-risks><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (REUTERS) - SolarWinds investors have sued the software company's directors, alleging they knew about and failed to monitor cyber-security risks to the company ahead of a breach that created ...</p>\n\n<a href=\"http://www.straitstimes.com/tech/tech-news/solarwinds-investors-allege-board-knew-about-cyber-risks\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SWI":"SolarWinds Corp"},"source_url":"http://www.straitstimes.com/tech/tech-news/solarwinds-investors-allege-board-knew-about-cyber-risks","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2181740934","content_text":"NEW YORK (REUTERS) - SolarWinds investors have sued the software company's directors, alleging they knew about and failed to monitor cyber-security risks to the company ahead of a breach that created a vulnerability in thousands of its customers' systems.\nThe lawsuit filed in Delaware on Thursday (Nov 4) appears to be the first based on records shareholders demanded from the company after Reuters reported last December that malicious code inserted into one of the company's software updates left United States government agencies and companies exposed.\nThe lawsuit names a mix of current and former directors as defendants.\nA SolarWinds spokesman said the company does not comment on pending litigation, but noted it is focused on \"deepening\" customer relationships and \"openly discussing our Secure by Design initiatives as we look to set the standard for secure software development\".\nLed by a Missouri pension fund, the investors allege that the board failed to implement procedures to monitor cyber-security risks, such as requiring the company's management to report on those risks regularly.\nThey are seeking damages on behalf of the company and to reform the company's policies on cyber-security oversight.\nThe lawsuit is the latest fallout over the breach of SolarWinds' software, which gave hackers access to the data of thousands of companies and government offices that used its products and which US officials have attributed to Russia.\nSolarWinds has said it is cooperating with investigations into the breach by the US Securities and Exchange Commission, Department of Justice and others. The company has moved to dismiss another shareholder lawsuit seeking damages for a decline in its share price.","news_type":1},"isVote":1,"tweetType":1,"viewCount":62,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850907143,"gmtCreate":1634542377971,"gmtModify":1634542378996,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"We can't copy his way, he has cash flow coming in even thou didn't buy stock now..but can you wait that long?","listText":"We can't copy his way, he has cash flow coming in even thou didn't buy stock now..but can you wait that long?","text":"We can't copy his way, he has cash flow coming in even thou didn't buy stock now..but can you wait that long?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850907143","repostId":"2176421001","repostType":4,"repost":{"id":"2176421001","pubTimestamp":1634525538,"share":"https://www.laohu8.com/m/news/2176421001?lang=&edition=full","pubTime":"2021-10-18 10:52","market":"us","language":"en","title":"Here's Why Warren Buffett Isn't Buying Many Stocks Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2176421001","media":"Motley Fool","summary":"And why you might want to copy the legendary investor's cautious approach.","content":"<p>Warren Buffett likes to drink Cherry Coke. He enjoys playing the ukelele. He likes to play bridge. But guess what Buffett doesn't seem to like doing very much these days? Buying stocks.</p>\n<p>The legendary investor has become one of the wealthiest people in the world by buying and holding stocks for his beloved <b>Berkshire Hathaway</b> (NYSE:BRK.A) (NYSE:BRK.B). However, Buffett isn't buying many stocks right now. And there's one simple reason why.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646095%2Fwarren-buffett-tmf.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: The Motley Fool.</span></p>\n<h2>Lots of cash, few new stocks</h2>\n<p>That reason definitely isn't that Buffett doesn't have enough cash at his disposal. Berkshire ended the second quarter with a cash stockpile (including cash, cash equivalents, and short-term investments) totaling $140.7 billion.</p>\n<p>However, in the second quarter of this year, Berkshire didn't use much of its cash buying stocks. Buffett added to Berkshire's stakes in only three companies: <b>Aon</b>, <b>Kroger</b>, and&nbsp;<b>RH</b>.</p>\n<p>Sure, Berkshire also reported a brand-new position in <b>Organon</b>. However, that new stock in the conglomerate's portfolio was the result of <b>Merck</b>'s&nbsp;spin-off of its women's health business.</p>\n<h2>A value investor at heart</h2>\n<p>Buffett's mentor was Benjamin Graham, the father of value investing. Over the years, Buffett has drifted away from a purist focus on stock valuations. However, it's probably fair to say that he's still a value investor at heart.</p>\n<p>With that in mind, take a look at the following chart. It shows the cyclically adjusted price-to-earnings (CAPE) for the S&amp;P 500 index over the last 60 years. The CAPE metric, popularized by Yale professor and author Robert Shiller, reflects the price of the S&amp;P 500 divided by the average earnings over the previous 10 years adjusted for inflation.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646095%2Fsp-500-cyclically-adjusted-price-to-earnings-cape.png&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"432\" width=\"100%\" height=\"auto\"><span>Data source: Robert Shiller, Yale University. Chart by author.</span></p>\n<p>Right now, the S&amp;P 500's valuation is at its second-highest level that Buffett has seen since he took over Berkshire Hathaway. The only time the CAPE for the index was higher was during the period leading up to and shortly after 2000.</p>\n<p>Of course, we all know what happened after the market valuation reached such a lofty level. Stocks plunged. It took seven years for the S&amp;P to fully bounce back. (And then it nose-dived again with the financial crisis of 2008 and 2009.)</p>\n<p>I don't know for sure if Buffett is looking at a chart like the one shown above. However, you can bet your bottom dollar that he's closely watching the overall market valuation. And he knows that buying stocks when they're really expensive usually doesn't work out all that well.</p>\n<h2>Be like Buffett?</h2>\n<p>Some investors might dismiss the idea of following a similar strategy as Buffett. They could correctly point out that Berkshire's total return over the last 10 years has lagged well behind that of the S&amp;P 500 index. And CAPE levels were higher during much of that period than they had been in a long time.</p>\n<p>However, my view is that Buffett's cautious approach makes sense right now. Stocks truly are trading at a premium that hasn't been seen in more than two decades. Historically, there's a compelling inverse correlation between the CAPE value of the S&amp;P 500 and the returns over subsequent years.</p>\n<p>The Oracle of Omaha is doing two things that other investors should seriously consider. First, he's built up a big cash stockpile. Second, he's still buying stocks but is much more judicious in doing so than in the past.</p>\n<p>No, I don't think every investor needs to necessarily have as great a percentage in cash as Buffett does with Berkshire. Neither do I believe that the only stocks worthy of buying are those that Berkshire has bought. But the more frothy valuations become, the more cash investors should accumulate and the more selective they should be about using that cash to buy stocks.</p>\n<p>I don't like Cherry Coke. I can't play the ukelele. And I've never played bridge in my life. I do know, though, that Buffett didn't achieve his tremendous success by overpaying for stocks. Investors who take the same perspective as the multibillionaire in this regard will probably be better off over the long run than those who don't.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Warren Buffett Isn't Buying Many Stocks Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Warren Buffett Isn't Buying Many Stocks Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-18 10:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/17/heres-why-warren-buffett-isnt-buying-many-stocks-r/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett likes to drink Cherry Coke. He enjoys playing the ukelele. He likes to play bridge. But guess what Buffett doesn't seem to like doing very much these days? Buying stocks.\nThe legendary ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/17/heres-why-warren-buffett-isnt-buying-many-stocks-r/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SPXU":"三倍做空标普500ETF","UPRO":"三倍做多标普500ETF","BRK.A":"伯克希尔","SH":"标普500反向ETF","IVV":"标普500指数ETF","SDS":"两倍做空标普500ETF","OEX":"标普100",".SPX":"S&P 500 Index","SSO":"两倍做多标普500ETF","OEF":"标普100指数ETF-iShares","BRK.B":"伯克希尔B"},"source_url":"https://www.fool.com/investing/2021/10/17/heres-why-warren-buffett-isnt-buying-many-stocks-r/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176421001","content_text":"Warren Buffett likes to drink Cherry Coke. He enjoys playing the ukelele. He likes to play bridge. But guess what Buffett doesn't seem to like doing very much these days? Buying stocks.\nThe legendary investor has become one of the wealthiest people in the world by buying and holding stocks for his beloved Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B). However, Buffett isn't buying many stocks right now. And there's one simple reason why.\nImage source: The Motley Fool.\nLots of cash, few new stocks\nThat reason definitely isn't that Buffett doesn't have enough cash at his disposal. Berkshire ended the second quarter with a cash stockpile (including cash, cash equivalents, and short-term investments) totaling $140.7 billion.\nHowever, in the second quarter of this year, Berkshire didn't use much of its cash buying stocks. Buffett added to Berkshire's stakes in only three companies: Aon, Kroger, and RH.\nSure, Berkshire also reported a brand-new position in Organon. However, that new stock in the conglomerate's portfolio was the result of Merck's spin-off of its women's health business.\nA value investor at heart\nBuffett's mentor was Benjamin Graham, the father of value investing. Over the years, Buffett has drifted away from a purist focus on stock valuations. However, it's probably fair to say that he's still a value investor at heart.\nWith that in mind, take a look at the following chart. It shows the cyclically adjusted price-to-earnings (CAPE) for the S&P 500 index over the last 60 years. The CAPE metric, popularized by Yale professor and author Robert Shiller, reflects the price of the S&P 500 divided by the average earnings over the previous 10 years adjusted for inflation.\nData source: Robert Shiller, Yale University. Chart by author.\nRight now, the S&P 500's valuation is at its second-highest level that Buffett has seen since he took over Berkshire Hathaway. The only time the CAPE for the index was higher was during the period leading up to and shortly after 2000.\nOf course, we all know what happened after the market valuation reached such a lofty level. Stocks plunged. It took seven years for the S&P to fully bounce back. (And then it nose-dived again with the financial crisis of 2008 and 2009.)\nI don't know for sure if Buffett is looking at a chart like the one shown above. However, you can bet your bottom dollar that he's closely watching the overall market valuation. And he knows that buying stocks when they're really expensive usually doesn't work out all that well.\nBe like Buffett?\nSome investors might dismiss the idea of following a similar strategy as Buffett. They could correctly point out that Berkshire's total return over the last 10 years has lagged well behind that of the S&P 500 index. And CAPE levels were higher during much of that period than they had been in a long time.\nHowever, my view is that Buffett's cautious approach makes sense right now. Stocks truly are trading at a premium that hasn't been seen in more than two decades. Historically, there's a compelling inverse correlation between the CAPE value of the S&P 500 and the returns over subsequent years.\nThe Oracle of Omaha is doing two things that other investors should seriously consider. First, he's built up a big cash stockpile. Second, he's still buying stocks but is much more judicious in doing so than in the past.\nNo, I don't think every investor needs to necessarily have as great a percentage in cash as Buffett does with Berkshire. Neither do I believe that the only stocks worthy of buying are those that Berkshire has bought. But the more frothy valuations become, the more cash investors should accumulate and the more selective they should be about using that cash to buy stocks.\nI don't like Cherry Coke. I can't play the ukelele. And I've never played bridge in my life. I do know, though, that Buffett didn't achieve his tremendous success by overpaying for stocks. Investors who take the same perspective as the multibillionaire in this regard will probably be better off over the long run than those who don't.","news_type":1},"isVote":1,"tweetType":1,"viewCount":102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864203238,"gmtCreate":1633101457952,"gmtModify":1633101459012,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Great news indeed!","listText":"Great news indeed!","text":"Great news indeed!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/864203238","repostId":"2172968435","repostType":4,"repost":{"id":"2172968435","pubTimestamp":1633097043,"share":"https://www.laohu8.com/m/news/2172968435?lang=&edition=full","pubTime":"2021-10-01 22:04","market":"us","language":"en","title":"Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News","url":"https://stock-news.laohu8.com/highlight/detail?id=2172968435","media":"Investing.com","summary":"By Geoffrey Smith\nInvesting.com -- Shares in the makers of Covid-19 vaccines all fell sharply in pre","content":"<p>By Geoffrey Smith</p>\n<p>Investing.com -- Shares in the makers of Covid-19 vaccines all fell sharply in premarket trading on Friday on expectations that Merck's experimental pill for treating the disease could radically undercut future demand for their drugs.</p>\n<p>By (8:45 AM ET 1345 GMT), Moderna (NASDAQ:MRNA) stock was down 4.9%, while BioNTech stock was down 5.3% and Pfizer (NYSE:PFE) stock was down 1.9%.&nbsp; Pfizer has traditionally been the least price-sensitive to vaccine news because it has many other revenue sources, whereas the other two are, for the present at least, pure plays on Covid-19 treatments.</p>\n<p>Merck (NYSE:MRK) had said earlier that an early-stage trial of its experimental pill had led to clear reductions in hospitalizations among the sample group, all of whom had taken it after developing moderate symptoms of Covid-19.</p>\n<p>The study was stopped early, as is often the case when an experimental drug shows signs of efficacy.</p>\n<p>Scientists have searched feverishly for a Covid-19 remedy that can be manufactured, distributed and administered at massive scale without arousing the suspicions and mistrust that often accompany new vaccines. Such a pill could transform the vaccination status of many poorer countries, where Covid-19 is still spreading more or less unimpeded due to the lack of vaccines in the developing world.</p>\n<p>Related Articles</p>\n<p>Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News</p>\n<p>Stocks under pressure as euro zone inflation hits 13-year high</p>\n<p>Merck's COVID-19 pill cuts risk of death, hospitalization by 50% in study</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-01 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-biontech-pfizer-fall-merck-085413419.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Geoffrey Smith\nInvesting.com -- Shares in the makers of Covid-19 vaccines all fell sharply in premarket trading on Friday on expectations that Merck's experimental pill for treating the disease ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-biontech-pfizer-fall-merck-085413419.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","NWS":"新闻集团","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/moderna-biontech-pfizer-fall-merck-085413419.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2172968435","content_text":"By Geoffrey Smith\nInvesting.com -- Shares in the makers of Covid-19 vaccines all fell sharply in premarket trading on Friday on expectations that Merck's experimental pill for treating the disease could radically undercut future demand for their drugs.\nBy (8:45 AM ET 1345 GMT), Moderna (NASDAQ:MRNA) stock was down 4.9%, while BioNTech stock was down 5.3% and Pfizer (NYSE:PFE) stock was down 1.9%.  Pfizer has traditionally been the least price-sensitive to vaccine news because it has many other revenue sources, whereas the other two are, for the present at least, pure plays on Covid-19 treatments.\nMerck (NYSE:MRK) had said earlier that an early-stage trial of its experimental pill had led to clear reductions in hospitalizations among the sample group, all of whom had taken it after developing moderate symptoms of Covid-19.\nThe study was stopped early, as is often the case when an experimental drug shows signs of efficacy.\nScientists have searched feverishly for a Covid-19 remedy that can be manufactured, distributed and administered at massive scale without arousing the suspicions and mistrust that often accompany new vaccines. Such a pill could transform the vaccination status of many poorer countries, where Covid-19 is still spreading more or less unimpeded due to the lack of vaccines in the developing world.\nRelated Articles\nModerna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News\nStocks under pressure as euro zone inflation hits 13-year high\nMerck's COVID-19 pill cuts risk of death, hospitalization by 50% in study","news_type":1},"isVote":1,"tweetType":1,"viewCount":2,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":897651394,"gmtCreate":1628915081118,"gmtModify":1633688510717,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"See no point of fighting these things..[摊手]&nbsp;[摊手]&nbsp;","listText":"See no point of fighting these things..[摊手]&nbsp;[摊手]&nbsp;","text":"See no point of fighting these things..[摊手] [摊手]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/897651394","repostId":"2159216739","repostType":2,"repost":{"id":"2159216739","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628901211,"share":"https://www.laohu8.com/m/news/2159216739?lang=&edition=full","pubTime":"2021-08-14 08:33","market":"us","language":"en","title":"Ford counterattacks in 'cruise' dispute with GM","url":"https://stock-news.laohu8.com/highlight/detail?id=2159216739","media":"Reuters","summary":"DETROIT, Aug 13 (Reuters) - Ford Motor Co said late on Friday it will ask the U.S. Patent Office to ","content":"<p>DETROIT, Aug 13 (Reuters) - Ford Motor Co said late on Friday it will ask the U.S. Patent Office to rescind trademarks obtained by rival General Motors Co for the terms \"Cruise\" and \"Super Cruise,\" escalating a brawl GM began by suing Ford over its use of \"Blue Cruise\" for an automated driving system.</p>\n<p>The legal fight between the two Detroit automakers turns on whether \"cruise\" is a generic term for technology that allows the car to take over some share of driving tasks from a human motorist.</p>\n<p>The clash underscores the intensity of competition among established automakers to be seen as leaders in automated driving technology, competitive with Silicon Valley rivals Tesla Inc, Alphabet Inc 's Waymo unit and others.</p>\n<p>GM filed a federal suit against Ford&nbsp;on July 24, accusing Ford of violating GM trademarks by using the name \"Blue Cruise\" for a system that enables hands-free driving.</p>\n<p>GM had previously trademarked \"Super Cruise\" for its hands-free, partially automated driving technology. It also has trademarked \"Cruise,\" the name of its robo-taxi unit in San Francisco.</p>\n<p>Ford reiterated on Friday its position that GM's suit is frivolous. The effort to nullify GM's trademarks for the use of the word \"cruise\" takes the fight to a new level.</p>\n<p>\"To defend itself, Ford has no choice but to ask the U.S. Patent and Trademark Office to rescind both of GM’s “Cruise” and “Super Cruise” trademark registrations that should have never been registered in the first place,\" Ford said. \"Any number of companies use the word 'cruise' in connection with driver assist technology.\"</p>\n<p>Among the examples Ford cited: \"Predictive Cruise,\" marketed by Mack Trucks; \"Smart Cruise Control\" marketed by Hyundai Motor Co , and Autocruise, used by auto supplier ZF Friedrichshafen AG.</p>\n<p>GM said Friday that Super Cruise \"has had a well established commercial presence since 2017,\" and added in a statement that the company \"remains committed to vigorously defending our brands and protecting the equity our products and technology have earned over several years in the market and that won’t change.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ford counterattacks in 'cruise' dispute with GM</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFord counterattacks in 'cruise' dispute with GM\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-14 08:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>DETROIT, Aug 13 (Reuters) - Ford Motor Co said late on Friday it will ask the U.S. Patent Office to rescind trademarks obtained by rival General Motors Co for the terms \"Cruise\" and \"Super Cruise,\" escalating a brawl GM began by suing Ford over its use of \"Blue Cruise\" for an automated driving system.</p>\n<p>The legal fight between the two Detroit automakers turns on whether \"cruise\" is a generic term for technology that allows the car to take over some share of driving tasks from a human motorist.</p>\n<p>The clash underscores the intensity of competition among established automakers to be seen as leaders in automated driving technology, competitive with Silicon Valley rivals Tesla Inc, Alphabet Inc 's Waymo unit and others.</p>\n<p>GM filed a federal suit against Ford&nbsp;on July 24, accusing Ford of violating GM trademarks by using the name \"Blue Cruise\" for a system that enables hands-free driving.</p>\n<p>GM had previously trademarked \"Super Cruise\" for its hands-free, partially automated driving technology. It also has trademarked \"Cruise,\" the name of its robo-taxi unit in San Francisco.</p>\n<p>Ford reiterated on Friday its position that GM's suit is frivolous. The effort to nullify GM's trademarks for the use of the word \"cruise\" takes the fight to a new level.</p>\n<p>\"To defend itself, Ford has no choice but to ask the U.S. Patent and Trademark Office to rescind both of GM’s “Cruise” and “Super Cruise” trademark registrations that should have never been registered in the first place,\" Ford said. \"Any number of companies use the word 'cruise' in connection with driver assist technology.\"</p>\n<p>Among the examples Ford cited: \"Predictive Cruise,\" marketed by Mack Trucks; \"Smart Cruise Control\" marketed by Hyundai Motor Co , and Autocruise, used by auto supplier ZF Friedrichshafen AG.</p>\n<p>GM said Friday that Super Cruise \"has had a well established commercial presence since 2017,\" and added in a statement that the company \"remains committed to vigorously defending our brands and protecting the equity our products and technology have earned over several years in the market and that won’t change.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"F":"福特汽车","GM":"通用汽车","GOOGL":"谷歌A","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2159216739","content_text":"DETROIT, Aug 13 (Reuters) - Ford Motor Co said late on Friday it will ask the U.S. Patent Office to rescind trademarks obtained by rival General Motors Co for the terms \"Cruise\" and \"Super Cruise,\" escalating a brawl GM began by suing Ford over its use of \"Blue Cruise\" for an automated driving system.\nThe legal fight between the two Detroit automakers turns on whether \"cruise\" is a generic term for technology that allows the car to take over some share of driving tasks from a human motorist.\nThe clash underscores the intensity of competition among established automakers to be seen as leaders in automated driving technology, competitive with Silicon Valley rivals Tesla Inc, Alphabet Inc 's Waymo unit and others.\nGM filed a federal suit against Ford on July 24, accusing Ford of violating GM trademarks by using the name \"Blue Cruise\" for a system that enables hands-free driving.\nGM had previously trademarked \"Super Cruise\" for its hands-free, partially automated driving technology. It also has trademarked \"Cruise,\" the name of its robo-taxi unit in San Francisco.\nFord reiterated on Friday its position that GM's suit is frivolous. The effort to nullify GM's trademarks for the use of the word \"cruise\" takes the fight to a new level.\n\"To defend itself, Ford has no choice but to ask the U.S. Patent and Trademark Office to rescind both of GM’s “Cruise” and “Super Cruise” trademark registrations that should have never been registered in the first place,\" Ford said. \"Any number of companies use the word 'cruise' in connection with driver assist technology.\"\nAmong the examples Ford cited: \"Predictive Cruise,\" marketed by Mack Trucks; \"Smart Cruise Control\" marketed by Hyundai Motor Co , and Autocruise, used by auto supplier ZF Friedrichshafen AG.\nGM said Friday that Super Cruise \"has had a well established commercial presence since 2017,\" and added in a statement that the company \"remains committed to vigorously defending our brands and protecting the equity our products and technology have earned over several years in the market and that won’t change.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":118,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":143669214,"gmtCreate":1625792032938,"gmtModify":1633937310924,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Recently most of the apparels stock are performing good[开心]&nbsp;[开心]&nbsp;","listText":"Recently most of the apparels stock are performing good[开心]&nbsp;[开心]&nbsp;","text":"Recently most of the apparels stock are performing good[开心] [开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/143669214","repostId":"1195657546","repostType":4,"repost":{"id":"1195657546","pubTimestamp":1625785913,"share":"https://www.laohu8.com/m/news/1195657546?lang=&edition=full","pubTime":"2021-07-09 07:11","market":"us","language":"en","title":"Stocks making the biggest moves after hours: Levi Strauss, General Motors, Accolade and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1195657546","media":"CNBC","summary":"Check out the companies making headlines after the bell Thursday:\nLevi Strauss— Shares of Levi Strau","content":"<div>\n<p>Check out the companies making headlines after the bell Thursday:\nLevi Strauss— Shares of Levi Strauss added 3.2% after the retailer crushed Wall Street expectations in itsfiscal second-quarter ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/08/stocks-making-the-biggest-moves-after-hours-levi-strauss-gm-accolade.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks making the biggest moves after hours: Levi Strauss, General Motors, Accolade and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks making the biggest moves after hours: Levi Strauss, General Motors, Accolade and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-09 07:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/07/08/stocks-making-the-biggest-moves-after-hours-levi-strauss-gm-accolade.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Check out the companies making headlines after the bell Thursday:\nLevi Strauss— Shares of Levi Strauss added 3.2% after the retailer crushed Wall Street expectations in itsfiscal second-quarter ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/08/stocks-making-the-biggest-moves-after-hours-levi-strauss-gm-accolade.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GM":"通用汽车","BGC":"BGC GROUP","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/07/08/stocks-making-the-biggest-moves-after-hours-levi-strauss-gm-accolade.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1195657546","content_text":"Check out the companies making headlines after the bell Thursday:\nLevi Strauss— Shares of Levi Strauss added 3.2% after the retailer crushed Wall Street expectations in itsfiscal second-quarter results. Levi reported adjusted earnings of 23 cents per share on revenue of $1.28 billion. Analysts expected earnings of 9 cents per share on revenue of $1.21 billion, according to Refinitiv.\nGeneral Motors— General Motors shares gained 1.3% after Wedbush initiated coverage of the stock with an outperform rating and $85 price target. That target implies an upside of more than 51% from Thursday's close. \"CEO Mary Barra along with other key executives has led the legacy auto company back to the top of the auto industry in the United States,\" Wedbush's Dan Ives said in a note.\nPriceSmart— Shares of PriceSmart rose 2.4% in thin trading on the back of the warehouse club operator’s third-quarter earnings report. PriceSmart posted earnings of 73 cents per share, compared with a FactSet estimate of 65 cents per share expectation.\nAccolade— Accolade shares added 1.2% in low-volume trading following after the company released its latest quarterly numbers. The health-care technology company reported revenue of of $59.5 million versus analysts’ $55.8 million estimate, according to FactSet. Accolade also posted a smaller-than-expected EBITDA loss.","news_type":1},"isVote":1,"tweetType":1,"viewCount":16,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}